; Tue Sep 24 14:44:09 PDT 2013
; 
;+ (version "3.4.8")
;+ (build "Build 629")

([Absence+of+Stage+D+HF] of  Diagnostic_Term_Metaclass

	(data_source clinical_assessment)
	(DiagnosticCriteria [KB_707214_Class0]))

([Acitve+prescription+for+ACE+and+ARB] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class250282]))

([Active+prescription+for+ACE+and+aldosterone+antagonists] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class100008]))

([Active+prescription+for+ARB+and+aldosterone+antagonist] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class100010]))

([African+american+and+moderate+symptoms+and+using+ACE%2C+BB%2C+diuretic] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element clinical_assessment)
	(DiagnosticCriteria [ATHENA_HF_Class70151]))

([African_American_and_IF_moderate_or_severe_symptoms_and_using_ACEI_BB] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class40000]))

([African_American_and_IF_moderate_or_severe_symptoms_and_using_ACEI_BB_diuretics] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class40000])
	(PrettyName "African American & (IF moderate symptoms) & using ACEI, BB, diuretics"))

([African_American_and_IF_NYHA_ClassIII_IV_symptoms_and_ACEorARB_BB] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class110004]))

([African_American_and_NYHA_III_IV_symptoms_ACE_or_ARB_and_BB] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class110014]))

([Angioedema+due+to+ADR+to+ACEI_OLD] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class140001])
	(PrettyName "Angioedema due to ADR to ACEI"))

([ATHENA_HF_Class0] of  Management_Guideline

	(clinical_algorithm [ATHENA_HF_Class1])
	(eligibility_criteria [KB_707214_Class0])
	(label "ATHENA Heart Failure Guideline"))

([ATHENA_HF_Class1] of  Management_Diagram

	(label "Athena Heart Failure clinical algorithm")
	(steps
		[ATHENA_HF_Class2]
		[ATHENA_HF_Class10003]
		[ATHENA_HF_Class10004]
		[ATHENA_HF_Class10005]
		[ATHENA_HF_Class30009]
		[ATHENA_HF_Class30017]
		[ATHENA_HF_Class50009]
		[ATHENA_HF_Class50087]
		[ATHENA_HF_Class50089]
		[ATHENA_HF_Class50097]
		[ATHENA_HF_Class60066]
		[ATHENA_HF_Class60068]
		[ATHENA_HF_Class60069])
	(transitions
		[ATHENA_HF_Class30016]
		[ATHENA_HF_Class20000]
		[ATHENA_HF_Class50014]
		[ATHENA_HF_Class50088]
		[ATHENA_HF_Class50090]
		[ATHENA_HF_Class50098]
		[ATHENA_HF_Class60067]
		[ATHENA_HF_Class60070]
		[ATHENA_HF_Class60071])
	(%3ADOCUMENTATION "5/20/13 removed arrow from Stage C Action Step to Stage B HF action"))

([ATHENA_HF_Class10000] of  Drug_Usage

	(Absolute_Contraindications
		Pregnancy
		Angioedema+due+to+ADR+to+ACEI
		Angioedema_due_to_ADR_to_ARB
		K%3E5)
	(collateral_actions
		[ATHENA_HF_Class110378]
		[ATHENA_HF_Class170010]
		[ATHENA_HF_Class170013]
		[ATHENA_HF_Class170009])
	(Compelling_Indications
		Myocardial_Infarction
		LVEF%3C%3D40+and+no+HF+symptoms
		HF+%28ICD9+or+symptoms%29+and+LVEF%3C%3D40)
	(Drug_Class_Name ACE_Inhibitors)
	(formulary_preferred_drug_in_class
		[ATHENA_HF_Class10001]
		[ATHENA_HF_Class50040]
		[ATHENA_HF_Class50042])
	(label "Ace_Inhibitor")
	(Relative_Contraindications Active+prescription+for+ARB+and+aldosterone+antagonist)
	(Relative_Indications
		HTN+and+LVH
		High+Risk+for+HF+and+DM%2C+HTN%2C+or+atherosclerotic+vascular+disease)
	(%3ADOCUMENTATION "StageC=ICD9 code AND assumes current or prior symptoms"))

([ATHENA_HF_Class100000] of  Management_Guideline

	(label "HF Performance Measures Outpatient"))

([ATHENA_HF_Class100002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class100853]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50018])
	(label "HF (ICD or NYHA Symptoms) and LVEF<=40 and no MI")
	(operator AND))

([ATHENA_HF_Class100004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class100853]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50011])
	(label "HF (ICD or Symptoms) and LVEF<=40 and MI")
	(operator AND))

([ATHENA_HF_Class100006] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00016]
		[ATHENA_HF_Class50026])
	(label "Active prescription for ACE OR ARB")
	(operator OR))

([ATHENA_HF_Class100008] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00016]
		[ATHENA_HF_Class110825])
	(label "Active prescription for ACE and aldosterone antagonists")
	(operator AND))

([ATHENA_HF_Class10001] of  Guideline_Drug

	(dose_level_ranges [ATHENA_HF_Class10002])
	(dose_strength_unit mg_per_mL)
	(generic_drug ACE_Inhibitors)
	(label "Captopril")
	(max_recommended_dose_level Low_Dose%28high%2Flow%29)
	(rule_in [ATHENA_HF_Class50011])
	(starting_dose 18.75))

([ATHENA_HF_Class100010] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50026]
		[ATHENA_HF_Class110825])
	(label "Active prescription for ARB and aldosterone antagonist")
	(operator AND))

([ATHENA_HF_Class100013] of  Presence_Criterion

	(domain_term Stage+D+Heart+Failure)
	(entry_type Note_Entry)
	(label "Stage D HF (refractory end stage HF)")
	(presence TRUE))

([ATHENA_HF_Class100014] of  Conditional_On_Screen_Message

	(description "Fluid management if using diuretics")
	(label "Fluid management if using diuretics")
	(message "Continue to manage diuretics and salt restriction for optimal volume control.  (Level of Evidence: C)")
	(message_type Class+I)
	(references
		[ATHENA_HF_Class110381]
		[ATHENA_HF_Class110389])
	(rule_in_condition [ATHENA_HF_Class70169]))

([ATHENA_HF_Class100015] of  Conditional_On_Screen_Message

	(description "fluid management NOT on diuretics")
	(label "fluid management NOT on diuretics")
	(message "Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)")
	(message_type Class+I)
	(references [ATHENA_HF_Class110381])
	(rule_in_condition [ATHENA_HF_Class100016]))

([ATHENA_HF_Class100016] of  Presence_Criterion

	(domain_term Diuretics)
	(entry_type Medication)
	(label "absence of diuretics")
	(presence FALSE))

([ATHENA_HF_Class10002] of  Range_Mapping_Entry

	(abstract_value Low_Dose%28high%2Flow%29)
	(label "Captopril_Increase_Dose")
	(lower_limit 18.75)
	(upper_limit 150.0))

([ATHENA_HF_Class10003] of  Scenario

	(consultation_template [ATHENA_HF_Class50000])
	(followed_by [ATHENA_HF_Class30009])
	(label "Stage B HF")
	(new_encounter TRUE)
	(precondition [ATHENA_HF_Class60053]))

([ATHENA_HF_Class10004] of  Scenario

	(consultation_template [ATHENA_HF_Class50074])
	(followed_by [ATHENA_HF_Class50087])
	(label "Stage C HF")
	(new_encounter TRUE)
	(precondition [ATHENA_HF_Class110175]))

([ATHENA_HF_Class10005] of  Scenario

	(followed_by [ATHENA_HF_Class60066])
	(label "Stage D HF")
	(new_encounter FALSE)
	(precondition [ATHENA_HF_Class100013]))

([ATHENA_HF_Class10006] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50031]
		[ATHENA_DM_Eye_Instance_40003])
	(label "High risk for developing heart failure")
	(operator OR))

([ATHENA_HF_Class10007] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class20005]
		[ATHENA_HF_Class20006]
		[ATHENA_HF_Class70628]
		[ATHENA_HF_Class50011]
		[ATHENA_HF_Class60044])
	(label "Structural Heart Disease")
	(operator OR))

([ATHENA_HF_Class10008] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class60088]
		[ATHENA_HF_Class10006]
		[ATHENA_HF_Class20008]
		[ATHENA_HF_Class60054])
	(label "Criteria for Stage A HF")
	(operator AND))

([ATHENA_HF_Class100223] of  N_ary_Criterion

	(criteria
		[athena_hypertension_203766]
		[ATHENA_HF_Class60012]
		[ATHENA_HF_Class60015]
		[ATHENA_HF_Class60016]
		[ATHENA_HF_Class200000])
	(label "ACE or ARB intolerance: ADR, hypotension, renal insuficiency")
	(operator OR))

([ATHENA_HF_Class100224] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class100223])
	(label "HF and LVEF<=40 and intolerance to ACE/ARB")
	(operator AND))

([ATHENA_HF_Class100394] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class70168]
		[ATHENA_HF_Class70002]
		[ATHENA_HF_Class270266]
		[ATHENA_HF_Class240003])
	(label "HF with persistent symptoms and LVEF<=40 and treated with conventional therapy")
	(operator AND))

([ATHENA_HF_Class100434] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class70145])
	(label "MI at least 40d old OR non ischemic dilated cardiomyopathy")
	(operator OR))

([ATHENA_HF_Class100847] of  Conditional_On_Screen_Message

	(description "rec cardiac resynchronization therapy")
	(label "rec cardiac resynchronization therapy")
	(message "Patients with LVEF of less than or equal to 35%, sinus rhythm, and NYHA functional class III ambulatory class IV symptoms\ndespite recommended optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than or equal to 0.12 seconds, should receive cardiac resynchronization therapy, with or without an ICD, unless contraindicated (203–218). (Level of Evidence: A)")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class100848]))

([ATHENA_HF_Class100848] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class100849]
		[ATHENA_HF_Class50049]
		[ATHENA_HF_Class70195])
	(label "LVEF<=35 & QRS >=0.12 & sinus rhythm & NYHA functional class III ambulatory class IV symptoms")
	(operator AND))

([ATHENA_HF_Class100849] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70192]
		[ATHENA_HF_Class100850])
	(label "cardiac dyssynchrony OR QRS>= 0.12")
	(operator OR))

([ATHENA_HF_Class100850] of  Presence_Criterion

	(domain_term cardiac+dyssynchrony)
	(entry_type Note_Entry)
	(label "presence of cardiac dyssynchrony")
	(presence TRUE))

([ATHENA_HF_Class100851] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70156]
		[ATHENA_HF_Class70186])
	(label "presence of moderate or severe symptoms")
	(operator OR))

([ATHENA_HF_Class100852] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class70198])
	(label "HF symptoms/HF and LVEF<=40")
	(operator AND))

([ATHENA_HF_Class100853] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class30004]
		[ATHENA_HF_Class60072])
	(label "HF ICD9 OR HF symptoms")
	(operator OR))

([ATHENA_HF_Class101051] of  Evaluate_Start_Activity

	(alternatives
		[ATHENA_HF_Class90000]
		[ATHENA_HF_Class240006]
		[ATHENA_HF_Class180005]
		[ATHENA_HF_Class110018]
		[ATHENA_HF_Class240002]
		[ATHENA_HF_Class260000])
	(label "Stage C drug recs Astronaut"))

([ATHENA_HF_Class102530] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00016]
		[athena_hypertension_INSTANCE_00017]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class70002])
	(label "LVEF<=40 & using ACE & using BB & persistent HF symptoms")
	(operator AND))

([ATHENA_HF_Class110000] of  Management_Guideline

	(label "HF Performance Measures Inpatient"))

([ATHENA_HF_Class110004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70168]
		[athena_hypertension_360026]
		[ATHENA_HF_Class110005]
		[ATHENA_HF_Class50025])
	(label "African American & (IF NYHA Class III-IV symtoms) & using (ACE or ARB)  & BB")
	(operator AND))

([ATHENA_HF_Class110005] of  Presence_Criterion

	(domain_term IF_NYHA_class_III_IV_symptoms)
	(entry_type Note_Entry)
	(label "IF NYHA class III-IV symptoms")
	(presence TRUE))

([ATHENA_HF_Class110014] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110015]
		[ATHENA_HF_Class220006]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class220005]
		[ATHENA_CKD_Instance_70022])
	(label "African american & NYHA II-IV & (ACE or ARB) & BB")
	(operator AND))

([ATHENA_HF_Class110015] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110016]
		[ATHENA_HF_Class110017])
	(label "NYHA class III or class IV")
	(operator OR))

([ATHENA_HF_Class110016] of  Presence_Criterion

	(domain_term NYHA+functional+class+III)
	(entry_type Note_Entry)
	(label "Presence of NYHA class III symptoms")
	(presence TRUE))

([ATHENA_HF_Class110017] of  Presence_Criterion

	(domain_term NYHA_functional_class_IV)
	(entry_type Note_Entry)
	(label "Presence of NYHA class IV symptoms")
	(presence TRUE))

([ATHENA_HF_Class110018] of  Drug_Usage

	(collateral_actions [KB_899077_Class9])
	(Compelling_Indications African_American_and_NYHA_III_IV_symptoms_ACE_or_ARB_and_BB)
	(Drug_Class_Name Hydralazine_and_nitrates)
	(label "Hydralazine and nitrates Astronaut II")
	(Relative_Indications LVEF%3C%3D40+and+contraindications+to+ACE%2FARB+%28hypotension%2C+renal+insufficiency+or+drug+intolerance%29))

([ATHENA_HF_Class110175] of  N_ary_Criterion

	(criteria
		[KB_707214_Class0]
		[ATHENA_HF_Class100853])
	(label "HF (ICD or signs/symptoms) AND NOT stage D")
	(operator AND))

([ATHENA_HF_Class110348] of  Conditional_On_Screen_Message

	(description "LVEF<30")
	(label "LVEF<30")
	(message "Most recent LVEF <30, patient should have a cardiac evaluation.")
	(message_type Recommendation)
	(references
		[ATHENA_HF_Class110364]
		[ATHENA_HF_Class110365])
	(rule_in_condition [ATHENA_HF_Class110349]))

([ATHENA_HF_Class110349] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "LVEF<30")
	(numeric_domain_term Left+Ventricular+Ejection+fraction)
	(operator %3C)
	(value 30.0))

([ATHENA_HF_Class110350] of  Conditional_On_Screen_Message

	(description "30<=LVEF<40")
	(label "30<=LVEF<40")
	(message "Patient has a low LVEF, consider cardiac evaluation or repeat left ventricular ejection fraction in about 3 months.")
	(message_type Recommendation)
	(references
		[ATHENA_HF_Class110365]
		[ATHENA_HF_Class110364])
	(rule_in_condition [ATHENA_HF_Class110351]))

([ATHENA_HF_Class110351] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class20004]
		[ATHENA_HF_Class110352])
	(label "30<=LVEF<40")
	(operator AND))

([ATHENA_HF_Class110352] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "LVEF>=30")
	(numeric_domain_term Left+Ventricular+Ejection+fraction)
	(operator %3E%3D)
	(value 30.0))

([ATHENA_HF_Class110353] of  Conditional_On_Screen_Message

	(description "rec add AA and using ACE")
	(label "rec add AA and using ACE")
	(message "K+ and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110381])
	(rule_in_condition [athena_hypertension_INSTANCE_00016]))

([ATHENA_HF_Class110354] of  Collateral_Action

	(actions [ATHENA_HF_Class110355])
	(label "target dose -authorized")
	(mood Authorized))

([ATHENA_HF_Class110355] of  On_Screen_Message

	(description "meet target dose, not max dose lisinopril")
	(label "meet target dose, not max dose lisinopril")
	(message "The target dose for lisinopril in heart failure management is 20mg/day. There were no demonstrated benefits using higher doses.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110362]))

([ATHENA_HF_Class110356] of  Collateral_Action

	(actions [ATHENA_HF_Class110357])
	(label "target dose - authorized")
	(mood Authorized))

([ATHENA_HF_Class110357] of  On_Screen_Message

	(description "target dose enalapril")
	(label "target dose enalapril")
	(message "The target dose for enalapril in heart failure management is 20mg/day. There were no demonstrated benefits using higher doses.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110362]))

([ATHENA_HF_Class110358] of  Collateral_Action

	(actions [ATHENA_HF_Class110357])
	(label "target dose- rec increase dose")
	(mood Recommend_Increase))

([ATHENA_HF_Class110359] of  Collateral_Action

	(actions [ATHENA_HF_Class110355])
	(label "target dose- rec increase dose")
	(mood Recommend_Increase))

([ATHENA_HF_Class110360] of  Collateral_Action

	(actions [ATHENA_HF_Class110361])
	(label "rec add bb")
	(mood Recommend_Add))

([ATHENA_HF_Class110361] of  Conditional_On_Screen_Message

	(description "add bb before inc dose ace")
	(label "add bb before inc dose ace")
	(message "In clinical trial, adding a beta blocker showed greater improvement in heart failure symptoms and outcomes versus increasing dose of ACE inhibitor.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110362])
	(rule_in_condition [athena_runtime_00103]))

([ATHENA_HF_Class110362] of  Supporting_Material

	(label "Elaine furmaga - consensus document"))

([ATHENA_HF_Class110363] of  Conditional_On_Screen_Message

	(description "ICD info to discuss with patient")
	(label "ICD info to discuss with patient")
	(message "Discussion should clarify in simple words exactly what an ICD does and doesn’t do.\nOf every 100 patients like yourself, during the next 5 years 7-8 will live longer because of device but:    \n- 28-30 will die anyway\n- Most (>50%) will never use their device but we have no sure way to know who they are\n- 8-10 will have an inappropriate shock which may increase the risk of dying \n- 4-10 will have other complications, some of which will be fatal\n- Your heart failure is more likely to worsen\n- Someday you may wish to have the defibrillation feature inactivated")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110364])
	(rule_in_condition [ATHENA_HF_Class70141]))

([ATHENA_HF_Class110364] of  Supporting_Material

	(label "Barry Massey- consensus document"))

([ATHENA_HF_Class110365] of  Supporting_Material

	(label "Paul Heindenrich - consensus document"))

([ATHENA_HF_Class110366] of  Conditional_On_Screen_Message

	(label "expectation of survival")
	(message "When evaluating expectation of survival with a good functional status, it is important that this estimation be based on non-cardiac survival.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110365])
	(rule_in_condition [ATHENA_HF_Class70141]))

([ATHENA_HF_Class110367] of  Order_TestProcedure

	(label "order ecg")
	(test_or_procedure EKG)
	(when [ATHENA_DM_Eye_Instance_100018]))

([ATHENA_HF_Class110368] of  Conditional_On_Screen_Message

	(description "order ecg")
	(label "order ecg")
	(message "Order ECG to determine QRS duration and candidacy for a CRT.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110365])
	(rule_in_condition [ATHENA_HF_Class110369]))

([ATHENA_HF_Class110369] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class70195])
	(label "LVEF<=35 and NYHA class 3 or 4")
	(operator AND))

([ATHENA_HF_Class110370] of  Collateral_Action

	(actions
		[ATHENA_HF_Class110371]
		[ATHENA_HF_Class110375]
		[ATHENA_HF_Class132286])
	(label "add dig")
	(mood Recommend_Add))

([ATHENA_HF_Class110371] of  Conditional_On_Screen_Message

	(label "inital dose recommendation digoxin when age>70, egfr<30 or lean body mass.")
	(message "Initial recommended dose of digoxin is 0.125mcg daily (or every other day).")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110362])
	(rule_in_condition [ATHENA_HF_Class110372]))

([ATHENA_HF_Class110372] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110373]
		[ATHENA_HF_Class110374])
	(label "age>70, egfr<30 or low lean body mass")
	(operator OR))

([ATHENA_HF_Class110373] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "age >70")
	(numeric_domain_term Age)
	(operator %3E)
	(value 70.0))

([ATHENA_HF_Class110374] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "egfr < 30")
	(numeric_domain_term eGFR)
	(operator %3C)
	(value 30.0))

([ATHENA_HF_Class110375] of  Parameterized_Message

	(label "parameterized message: dig dose if age>70, egfr<30 or lean body mass")
	(message_type Recommendation)
	(parameterized_message [ATHENA_HF_Class110376])
	(references [ATHENA_HF_Class110362]))

([ATHENA_HF_Class110376] of  Parameterized_String

	(variables [ATHENA_HF_Class110377]))

([ATHENA_HF_Class110377] of  Variable
)

([ATHENA_HF_Class110378] of  Collateral_Action

	(actions
		[ATHENA_HF_Class110379]
		[ATHENA_HF_Class110380])
	(label "rec add ace")
	(mood Recommend_Add))

([ATHENA_HF_Class110379] of  On_Screen_Message

	(description "rec add ace: dose adjustent based on kidney function")
	(label "rec add ace: dose adjustent based on kidney functio")
	(message "Refer to specific ACE Inhibitor dose adjustments based on kidney function.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110362]))

([ATHENA_HF_Class110380] of  On_Screen_Message

	(description "monitoring renal function and K for ACEI")
	(label "monitoring renal function and K for ACEI")
	(message "Renal function and\nserum potassium should be assessed within 1 to 2 weeks of\ninitiation of therapy and periodically thereafter, especially in\npatients with preexisting hypotension, hyponatremia, diabetes\nmellitus, or azotemia or in those taking potassium\nsupplements.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110381])
	(%3ADOCUMENTATION "ACC/AHA pg e26"))

([ATHENA_HF_Class110381] of  Supporting_Material

	(label "ACC/AHA 2009"))

([ATHENA_HF_Class110382] of  Collateral_Action

	(actions
		[ATHENA_HF_Class110383]
		[ATHENA_HF_Class240016])
	(label "add hydralazine and nitrates")
	(mood Recommend_Add))

([ATHENA_HF_Class110383] of  On_Screen_Message

	(description "rec add hydralazine and nitrates- dose suggsetions")
	(label "rec add hydralazine and nitrates- dose suggsetions")
	(message "Recommend starting with hydralazine 25mg tid and nitrates 10mg tid. Would not go much above hydralazine 50mg tid and nitrates 40mg tid. Titrate after a month. Beta blockers can avoid the tachycardia caused by hydralazine and nitrates.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110364]))

([ATHENA_HF_Class110384] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class110388])
	(label "Age>70: dose adjsutment may be necessary"))

([ATHENA_HF_Class110386] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class110384]))

([ATHENA_HF_Class110387] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class50084]))

([ATHENA_HF_Class110388] of  Conditional_On_Screen_Message

	(description "age > 70, dose adjustments may be necessary")
	(label "age > 70, dose adjustments may be necessary")
	(message "For patients older than 70 years be alert of the possible need for dose adjustment based on eGFR.")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110389]))

([ATHENA_HF_Class110389] of  Supporting_Material

	(label "Mary Goldstein - consensus"))

([ATHENA_HF_Class110390] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class110392])
	(label "BNP monitoring"))

([ATHENA_HF_Class110391] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class110390]))

([ATHENA_HF_Class110392] of  On_Screen_Message

	(description "BNP monitoring")
	(label "BNP monitoring")
	(message "There is somewhat more evidence, and home self bnp monitoring is in development.   While I don’t do it, I think that it wouldn’t be bad to get a baseline BNP on a newly diagnosed patient.  Very high ones mean something and woulde make me more aggressive.  I prefer history and PE, but there may be value for PCP who may have less time for history and less skill with PE.")
	(message_type Recommendation))

([ATHENA_HF_Class110411] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class110414])
	(label "not use nutritional supplements")
	(rule_in [criterion_INSTANCE_00001])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class110413] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class110411]))

([ATHENA_HF_Class110414] of  On_Screen_Message

	(description "not use nutritional supplements")
	(label "not use nutritional supplements")
	(message "Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of\nEvidence: C)")
	(message_type Class+III))

([ATHENA_HF_Class110823] of  Conditional_On_Screen_Message

	(description "Combined use ACEI, ARB and aldosterone antagonist not rec")
	(label "Combined use ACEI, ARB and aldosterone antagonist not rec")
	(message "Routine combined use of an ACEI, ARB, and aldosterone antagonist is NOT RECOMMENDED for patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)")
	(message_type Class+III)
	(rule_in_condition [ATHENA_HF_Class110824]))

([ATHENA_HF_Class110824] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class50026]
		[ATHENA_HF_Class110825])
	(label "On ACEI, ARB and aldosterone antagonist")
	(operator AND))

([ATHENA_HF_Class110825] of  Presence_Criterion

	(domain_term aldosterone+antagonist)
	(entry_type Medication)
	(label "presence of aldosterone antagonist")
	(presence TRUE))

([ATHENA_HF_Class120000] of  Management_Guideline

	(clinical_algorithm [ATHENA_HF_Class130000])
	(drug_usages
		[ATHENA_HF_Class260000]
		[ATHENA_HF_Class240006]
		[ATHENA_HF_Class240002]
		[ATHENA_HF_Class90000]
		[ATHENA_HF_Class110018]
		[ATHENA_HF_Class180005]
		[ATHENA_HF_Class220018])
	(label "ATHENA HF Astronaut")
	(%3ADOCUMENTATION "Encode only N recommendations, from ACC_AHA_HF 2009, using classes already encoded in CDS\nScenario = Stage C HF 4\n1. ACEI or ARB are recommendedin patients with current or prior symptoms of HF and reduced LVEF*, unless contraindicated\n2. Beta blockers bisoprolol, carvedilol, or sustained release metoprolol succinate arerecommended for all stable patients with current or prior symptoms of HF and reduced LVEF*, unless contraindicated\n3. Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF** who can be carefully monitored for preserved renal function and normal potassium concentration. Removed requirement for symptoms; instead issue \"IF_symptoms_exist\" message\n4. Combination of hydralazine and nitrates is recommended for  African-Americans, NYHA Class III-IV symptoms [1] on optimal therapy with (ACEIs OR ARB) and beta blockers.  Removed requirement for symptoms; instead issue \"IF_symptoms_exist\" message. from 2013 ACCF/AHA HF guidelines\n5. Implantable cardioverter-defibrillator (ICD) therapy is recommended for primary prevention; use IF NHY symptoms; on screen message[\\\\\n6. CRT with or without an ICD is reasonable for the treatment of NYHA functional class III or ambulatory class IV heart failure symptoms (IF_symptoms exist bypass); conditional on screen message\n\nFootnotes\n*LVEF<=40, differs from PM (< rather than <=) to be more inclusive \n**LVEF<=35, consistent with PM\n[1] or LVEF<=40, added in CDS; LVEF <40 in PM\n\nRev68 (dated 4/22/13) retrieved from SVN\n\"IF_symptoms\" moved from supercalss \"HF signs and symptoms\" to Syndrome"))

([ATHENA_HF_Class120002] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "LVEF<40")
	(numeric_domain_term EjectionFraction)
	(operator %3C)
	(valid_window [ATHENA_DM_Eye_Instance_80016])
	(value 40.0))

([ATHENA_HF_Class120005] of  Presence_Criterion

	(entry_type Note_Entry)
	(label "Presence HF PM Outpatient")
	(presence TRUE))

([ATHENA_HF_Class120883] of  Conditional_On_Screen_Message

	(description "Acute MI, use contemporary guidelines")
	(label "Acute MI, use contemporary guidelines")
	(message "Patients who have not developed HF symptoms should be treated according to contemporary guidelines after an acute MI. (Level of Evidence: C).")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class90385]))

([ATHENA_HF_Class121650] of  Presence_Criterion

	(domain_term structural+heart+disease)
	(entry_type Note_Entry)
	(label "presence of structural heart disease")
	(presence TRUE))

([ATHENA_HF_Class122379] of  Presence_Criterion

	(domain_term NYHA+class+I)
	(entry_type Note_Entry)
	(label "presence of NYHA functional class I")
	(presence TRUE))

([ATHENA_HF_Class124161] of  Presence_Criterion

	(domain_term nonsteroidal+anti-inflammatory+drugs)
	(entry_type Medication)
	(label "presence of NSAIDs")
	(mood Authorized)
	(presence TRUE))

([ATHENA_HF_Class124162] of  Presence_Criterion

	(domain_term calcium+channel+blockers+with+negative+inotropic+effects)
	(entry_type Medication)
	(label "presence of cardiotoxic CCB")
	(mood Authorized)
	(presence TRUE))

([ATHENA_HF_Class124163] of  Presence_Criterion

	(domain_term antiarrhythmic+drugs)
	(entry_type Medication)
	(label "presence of cardiotoxic antiarrhythmic drugs")
	(mood Authorized)
	(presence TRUE))

([ATHENA_HF_Class124167] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class124162]
		[ATHENA_HF_Class124163]
		[ATHENA_HF_Class170002]
		[ATHENA_HF_Class260070])
	(label "presence of drugs that adversely effect HF")
	(operator OR))

([ATHENA_HF_Class124168] of  Conditional_On_Screen_Message

	(description "Use of drugs adversely affect HF status")
	(label "Use of drugs adversely affect HF status")
	(message "Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most\ncalcium channel blocking drugs). (Level of Evidence: B)")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class124167]))

([ATHENA_HF_Class130000] of  Management_Diagram

	(label "ATHENA HF Astronaut algorithm")
	(steps
		[ATHENA_HF_Class130001]
		[ATHENA_HF_Class130002]
		[ATHENA_HF_Class250000]
		[ATHENA_HF_Class270000]
		[ATHENA_HF_Class130004]
		[ATHENA_HF_Class330002]
		[ATHENA_HF_Class340249]
		[ATHENA_HF_Class340250]
		[ATHENA_HF_Class340248])
	(transitions
		[ATHENA_HF_Class130003]
		[ATHENA_HF_Class260001]
		[ATHENA_HF_Class310000]
		[ATHENA_HF_Class330001]
		[ATHENA_HF_Class330004]
		[ATHENA_HF_Class350555]
		[ATHENA_HF_Class350556]))

([ATHENA_HF_Class130001] of  Scenario

	(followed_by [ATHENA_HF_Class130002])
	(label "Stage C HF 4")
	(new_encounter TRUE)
	(precondition [ATHENA_HF_Class110175]))

([ATHENA_HF_Class130002] of  Choice_Step

	(branches
		[ATHENA_HF_Class250000]
		[ATHENA_HF_Class270000]
		[ATHENA_HF_Class130004]
		[ATHENA_HF_Class330002])
	(label "Stage C HF branches"))

([ATHENA_HF_Class130003] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130001])
	(%3ATO [ATHENA_HF_Class130002]))

([ATHENA_HF_Class130004] of  Action_Choice

	(actions
		[ATHENA_HF_Class101051]
		[ATHENA_HF_Class160002]
		[ATHENA_HF_Class230001]
		[ATHENA_HF_Class230003]
		[ATHENA_HF_Class230005])
	(label "Stage C HF rec LVEF <= 40")
	(strict_rule_in_condition [ATHENA_HF_Class280000]))

([ATHENA_HF_Class130006] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class130004]))

([ATHENA_HF_Class130007] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class133534]
		[ATHENA_HF_Class100851]
		[ATHENA_HF_Class70142])
	(label "LVEF <=35 & HF & (moderate or severe symptoms) & creatinine low & K<5")
	(operator AND))

([ATHENA_HF_Class132286] of  On_Screen_Message

	(description "Digoxin StageC Class IIA 4")
	(label "Digoxin StageC Class IIA 4")
	(message "Digitalis can be beneficial in patients with current or prior symptoms of HF and reduced LVEF to decrease hospitalizations for HF (Level of Evidence: B).  ADD ADDL INFO from HF experts to help guide choice of when to add dig")
	(message_type Recommendation)
	(references [ATHENA_HF_Class110381]))

([ATHENA_HF_Class133534] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class133535]
		[ATHENA_HF_Class133536])
	(label "(creatinine <=2.5 males OR <=2 females) and K<5")
	(operator AND))

([ATHENA_HF_Class133535] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "K<5")
	(numeric_domain_term Potassium)
	(operator %3C)
	(value 5.0))

([ATHENA_HF_Class133536] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class133537]
		[ATHENA_HF_Class133539])
	(label "creatinine <=2.5 males OR  <=2 females")
	(operator OR))

([ATHENA_HF_Class133537] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00102]
		[ATHENA_HF_Class133538])
	(label "male and creatinine <=2.5")
	(operator AND))

([ATHENA_HF_Class133538] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "creatinine <=2.5")
	(numeric_domain_term Creatinine)
	(operator %3C%3D)
	(value 2.5))

([ATHENA_HF_Class133539] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00100]
		[ATHENA_HF_Class133540])
	(label "female and creatinine<=2")
	(operator AND))

([ATHENA_HF_Class133540] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "creatinine <=2")
	(numeric_domain_term Creatinine)
	(operator %3C%3D)
	(value 2.0))

([ATHENA_HF_Class140000] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "Presence of angioedema due to ADR to ACEI")
	(%3APAL-RANGE "(defrange ?reaction :FRAME Adverse_Reaction)")
	(%3APAL-STATEMENT "(exists ?reaction \n        (and (= (patient_id ?reaction) $patient_id) \n             (or (= (substance ?reaction) ACE_Inhibitors)\n                 ( subclass-of (substance ?reaction) ACE_Inhibitors))\n             (or (= (domain_term ?reaction) Angioedema))\n        )\n)"))

([ATHENA_HF_Class140001] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "Presence of angioedema due to ADR to ACEI")
	(PAL_constraint [ATHENA_HF_Class140000]))

([ATHENA_HF_Class140004] of  Conditional_Goal
)

([ATHENA_HF_Class140006] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "Age >=21")
	(numeric_domain_term Age)
	(operator %3E%3D)
	(value 21.0))

([ATHENA_HF_Class140007] of  Presence_Criterion

	(domain_term Outpatient_Encounter)
	(entry_type Note_Entry)
	(label "Outpatient encounter in past 12m")
	(period [ATHENA_DM_Eye_Instance_30019])
	(presence TRUE))

([ATHENA_HF_Class140008] of  N_ary_Criterion

	(label "Joint HF exclusions")
	(operator OR))

([ATHENA_HF_Class140009] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class140010]
		[ATHENA_HF_Class140011]
		[ATHENA_HF_Class140012])
	(label "Prescription for carvedilol OR bisoprolol OR sustained release metoprolol succinate")
	(operator OR))

([ATHENA_HF_Class140010] of  Presence_Criterion

	(domain_term carvedilol)
	(entry_type Medication)
	(label "prescription for carvedilol in past year")
	(mood Authorized)
	(period [ATHENA_DM_Eye_Instance_30019])
	(presence TRUE))

([ATHENA_HF_Class140011] of  Presence_Criterion

	(domain_term bisoprolol)
	(entry_type Medication)
	(label "prescription for bisoprolol in past year")
	(mood Authorized)
	(period [ATHENA_DM_Eye_Instance_30019])
	(presence TRUE))

([ATHENA_HF_Class140012] of  Presence_Criterion

	(domain_term sustained+release+metoprolol+succinate)
	(entry_type Medication)
	(label "prescription for sustained release metoprolol succinate")
	(mood Authorized)
	(period [ATHENA_DM_Eye_Instance_30019])
	(presence TRUE))

([ATHENA_HF_Class140013] of  N_ary_Criterion

	(criteria
		[athena_hypertension_203766]
		[ATHENA_HF_Class140014])
	(label "ACE AND ARB ADR/allergy")
	(operator AND))

([ATHENA_HF_Class140014] of  Presence_Criterion

	(domain_term Angiotensin_II_receptor_blockers)
	(entry_type Adverse_Reaction)
	(label "ADR ARB")
	(presence TRUE))

([ATHENA_HF_Class140015] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "most recent K >=5.5")
	(numeric_domain_term Potassium)
	(operator %3E%3D)
	(value 5.5))

([ATHENA_HF_Class144252] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70036]
		[ATHENA_HF_Class60088])
	(label "No HF AND (DM or HTN or atherosclerotic vascular diseas)")
	(operator AND))

([ATHENA_HF_Class150000] of  Action_Choice

	(actions [ATHENA_HF_Class70140])
	(label "ICD primary prevention")
	(strict_rule_in_condition [ATHENA_HF_Class50043]))

([ATHENA_HF_Class150001] of  Drug_Usage

	(Absolute_Contraindications
		Female+and+most+recent+creatinine++%3E2
		Male+and+most+recent+creatinine%3E2.5
		Acitve+prescription+for+ACE+and+ARB
		Renal_Insufficiency)
	(collateral_actions [ATHENA_HF_Class70166])
	(Compelling_Indications HF_and_+LVEF%3C%3D35_and_IF_NYHA_Class_III_or__IV_or_II_and_elevated_BNP)
	(Drug_Class_Name aldosterone+antagonist)
	(label "Aldosterone antagonist Astronaut"))

([ATHENA_HF_Class150003] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class150004]
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class133536]
		[athena_hypertension_360026])
	(label "LVEF <=35 & HF & (IF moderate or severe symptoms) & creatinine low & K<5")
	(operator AND))

([ATHENA_HF_Class150004] of  Presence_Criterion

	(domain_term If_moderate_or_severe_symptoms_are_present)
	(entry_type Note_Entry)
	(label "If moderate or severe symptoms are present")
	(presence TRUE))

([ATHENA_HF_Class150007] of  Drug_Usage

	(collateral_actions [ATHENA_HF_Class110382])
	(Compelling_Indications African_American_and_IF_NYHA_ClassIII_IV_symptoms_and_ACEorARB_BB)
	(Drug_Class_Name Hydralazine_and_nitrates)
	(label "Hydralazine and nitrates Astronaut")
	(Relative_Indications
		LVEF%3C%3D40+%26+using+ACE+%26+using+BB+%26+HF+symptoms
		LVEF%3C%3D40+and+contraindications+to+ACE%2FARB+%28hypotension%2C+renal+insufficiency+or+drug+intolerance%29)
	(%3ADOCUMENTATION "Compelling indication ACCF/AHA 2013"))

([ATHENA_HF_Class150009] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class70169]
		[ATHENA_HF_Class70168]
		[ATHENA_HF_Class150004]
		[athena_hypertension_360026])
	(label "African American & (IF moderate or severe symptoms) & using ACE & BB & diuretics")
	(operator AND))

([ATHENA_HF_Class150011] of  Presence_Criterion

	(domain_term If_moderate_symptoms_+are_present)
	(entry_type Note_Entry)
	(label "If moderate symptoms are present")
	(presence TRUE))

([ATHENA_HF_Class160000] of  On_Screen_Message

	(fine-grain_priority 9)
	(label "NYHA classification")
	(message "Functional Capacity .....................................................Objective Assessment\nClass I. Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	A. No objective evidence of cardiovascular disease.\nClass II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	B. Objective evidence of minimal cardiovascular disease.\nClass III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	C. Objective evidence of moderately severe cardiovascular disease.\nClass IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	D. Objective evidence of severe cardiovascular disease.")
	(message_type Recommendation))

([ATHENA_HF_Class160001] of  Conditional_On_Screen_Message

	(fine-grain_priority 9)
	(label "CRT NYHA classification Astronaut")
	(message "Functional Capacity .....................................................Objective Assessment\nClass I. Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	A. No objective evidence of cardiovascular disease.\nClass II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	B. Objective evidence of minimal cardiovascular disease.\nClass III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	C. Objective evidence of moderately severe cardiovascular disease.\nClass IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	D. Objective evidence of severe cardiovascular disease.")
	(message_type Recommendation)
	(rule_in_condition [ATHENA_HF_Class70189]))

([ATHENA_HF_Class160002] of  Conditional_On_Screen_Message

	(fine-grain_priority 9)
	(label "NYHA classification")
	(message "Functional Capacity \\t Objective Assessment\nClass I. \\t Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	A. No objective evidence of cardiovascular disease.\nClass II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	B. Objective evidence of minimal cardiovascular disease.\nClass III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	C. Objective evidence of moderately severe cardiovascular disease.\nClass IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	D. Objective evidence of severe cardiovascular disease.")
	(message_type Recommendation)
	(rule_in_condition [criterion_INSTANCE_00001]))

([ATHENA_HF_Class160325] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class150000]))

([ATHENA_HF_Class160433] of  Conditional_On_Screen_Message

	(label "ICD primary prev rec Stage C Astronaut")
	(message "Class I:  Implantable cardioverter-defibrillator therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in patients with non-ischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI, a LVEF less than or equal to 35%, and ASSUMING NYHA functional class II or III symptoms while receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A).  PRESENCE OF HF SYMPTOMS DATA IS NOT AVAILABLE AND IS ASSUMED TO BE PRESENT.")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class170331]))

([ATHENA_HF_Class161507] of  Presence_Criterion

	(domain_term Myocardial_Infarction)
	(entry_type Note_Entry)
	(label "Presence of MI at least 40 days old")
	(period [ATHENA_HF_Class50057])
	(presence TRUE))

([ATHENA_HF_Class161508] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70145]
		[ATHENA_HF_Class161615])
	(label "Presence of MI at least 40 days old or nonischemic dilated cardiomyopathy")
	(operator OR))

([ATHENA_HF_Class161615] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class161616]
		[ATHENA_HF_Class50011])
	(label "Presence of MI gt 40 days old")
	(operator AND))

([ATHENA_HF_Class161616] of  Presence_Criterion

	(domain_term Myocardial_Infarction)
	(entry_type Note_Entry)
	(label "Absence of MI within 41 days")
	(period [ATHENA_HF_Class50057])
	(presence FALSE))

([ATHENA_HF_Class170000] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class133536]
		[athena_hypertension_477393])
	(label "(Creatinine<=2.5 and male or creatinine <=2.0 and female) or eGFR>30")
	(operator OR))

([ATHENA_HF_Class170001] of  Presence_Criterion

	(domain_term aspirin)
	(entry_type Medication)
	(label "Absence of aspirin")
	(presence FALSE))

([ATHENA_HF_Class170002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class124161]
		[ATHENA_HF_Class170001])
	(label "Presence of NSAID and Absence of aspirin")
	(operator AND))

([ATHENA_HF_Class170003] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class124162]
		[ATHENA_HF_Class124163]
		[ATHENA_HF_Class170002]
		[ATHENA_HF_Class260070])
	(label "presence of drugs that adversely effect HF Astrpnaut")
	(operator OR))

([ATHENA_HF_Class170004] of  Conditional_On_Screen_Message

	(description "Use of drugs adversely affect HF status Astronaut")
	(label "Use of drugs adversely affect HF status Astronaut")
	(message "Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs (not aspirin), most antiarrhythmic drugs,  most\ncalcium channel blocking drugs (except amlodipine) and thiazolidinediones). (Level of Evidence: B)")
	(message_type Class+III)
	(rule_in_condition [ATHENA_HF_Class170003])
	(%3ADOCUMENTATION "updated from 7.3.2.9, ACCFAHA 2013"))

([ATHENA_HF_Class170005] of  Consultation_Guideline

	(first_step [ATHENA_HF_Class170006])
	(label "Stage C consultation template Astronaut")
	(steps
		[ATHENA_HF_Class170006]
		[ATHENA_HF_Class170007]
		[ATHENA_HF_Class200011])
	(transitions
		[ATHENA_HF_Class170008]
		[ATHENA_HF_Class200012]))

([ATHENA_HF_Class170006] of  Consultation_Branch_Step

	(branches
		[ATHENA_HF_Class170007]
		[ATHENA_HF_Class200011])
	(label "Stage C HF Astronaut")
	(selection_method all_of))

([ATHENA_HF_Class170007] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class170004])
	(label "Drugs to avoid in HF")
	(rule_in [ATHENA_HF_Class170003]))

([ATHENA_HF_Class170008] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class170006])
	(%3ATO [ATHENA_HF_Class170007]))

([ATHENA_HF_Class170009] of  Collateral_Action

	(actions [ATHENA_HF_Class170020])
	(label "ACE inhibitor and NSAID general collateral message")
	(mood Recommend_Add))

([ATHENA_HF_Class170010] of  Collateral_Action

	(actions [ATHENA_HF_Class170011])
	(label "ACE inhibitor and Presence NSAID primary message")
	(mood Recommend_Add))

([ATHENA_HF_Class170011] of  Conditional_On_Screen_Message

	(description "Use of ACE inhibitor and NSAID Astronaut")
	(label "Use of ACE inhibitor and NSAID Astronaut")
	(message "Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs")
	(message_type Primary_Recommendation)
	(rule_in_condition [ATHENA_HF_Class170012]))

([ATHENA_HF_Class170012] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00016]
		[ATHENA_HF_Class170002])
	(label "Presence of ACE inhibitor and NSAID not aspirin")
	(operator AND))

([ATHENA_HF_Class170013] of  Collateral_Action

	(actions [ATHENA_HF_Class170016])
	(label "Add ACE inhibitor while on NSAID warning")
	(mood Recommend_Add))

([ATHENA_HF_Class170016] of  Conditional_On_Screen_Message

	(label "Add ACE inhibitor while on NSAID not aspirin primary message")
	(message "Presence of NSAID detected.  Warning:  Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs")
	(message_type Primary_Recommendation)
	(rule_in_condition [ATHENA_HF_Class170002]))

([ATHENA_HF_Class170017] of  Consultation_Action_Step

	(label "NSAID general collateral message"))

([ATHENA_HF_Class170018] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class170006])
	(%3ATO [ATHENA_HF_Class170017]))

([ATHENA_HF_Class170019] of  Presence_Criterion

	(domain_term nonsteroidal+anti-inflammatory+drugs)
	(entry_type Medication)
	(label "Absence of NSAID")
	(presence FALSE))

([ATHENA_HF_Class170020] of  Conditional_On_Screen_Message

	(description "Absence of NSAID HF collateral message Astronaut")
	(label "Absence of NSAID HF collateral message Astronaut")
	(message "Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs")
	(message_type Recommendation)
	(rule_in_condition [ATHENA_HF_Class170019]))

([ATHENA_HF_Class170329] of  On_Screen_Message

	(label "rec add hyralazine_nitrates IF symptoms")
	(message "Class I Recommendation for hydralazine and nitrates for patients who are African American, have an active prescription of an ACE inhibitor and beta blocker and diuretics and an ASSUMMPTION that patient is experiencing moderate or severe HF symptoms.  Presence/absence of HF symptoms data not available for this recommendation")
	(message_type Class+I)
	(%3ADOCUMENTATION "- 4/1/13 message to inform that assumes presence of symptoms; for Astronaut"))

([ATHENA_HF_Class170330] of  On_Screen_Message

	(label "rec add aldosterone antagonist IF symptoms")
	(message "Class I recommendation for aldosterone antagonist for patietst with HF, LVEF<=35, (creatinine <=2.5 and male) or (creatine <=2 and femalel) and an ASSUMPTiON that  patient is experiencing moderate or severe HF symptoms.  Presence/absence of HF symptoms data not available for this recommendation.")
	(message_type Class+I)
	(%3ADOCUMENTATION "- 4/1/13 message to inform that assumes presence of symptoms; for Astronaut"))

([ATHENA_HF_Class170331] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class161508]
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class170335])
	(label "(MI 40 days old OR non-ischemid dilated cardiomyopathy) & LVEF le 35 & IF symptoms")
	(operator AND))

([ATHENA_HF_Class170334] of  Presence_Criterion

	(domain_term IF_NYHA_functional_class_III_or+_mbulatory_class_IV_heart_failure_symptoms)
	(entry_type Note_Entry)
	(label "IF NYHA functional class III or ambulatory class IV heart failure symptoms")
	(presence TRUE))

([ATHENA_HF_Class170335] of  Presence_Criterion

	(domain_term IF_NYHA_functional_class_II_o_+III_symptoms)
	(entry_type Note_Entry)
	(label "IF NYHA functional class II or III symptoms")
	(presence TRUE))

([ATHENA_HF_Class170336] of  Conditional_On_Screen_Message

	(label "CRT when LVEF<=35% and QRS>=0.12s and atrial fibrillation Astronaut")
	(message "Class IIa:  For patients who have LVEF less than or equal to 35%, a QRS duration of greater than or equal to 0.12 seconds, and atrial fibrillation (AF), CRT with or without an ICD is reasonable for the treatment of those patients with NYHA functional class III or ambulatory class IV heart failure symptoms on optimal recommended medical therapy. (Level of Evidence: B).  PRESENCE OF HF SYMPTOMS DATA IS NOT AVAILABLE AND IS ASSUMED TO BE PRESENT.")
	(message_type Class+II+a)
	(rule_in_condition [ATHENA_HF_Class70189])
	(%3ADOCUMENTATION "- CRT Astronaut IF NHY symptoms present"))

([ATHENA_HF_Class180000] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "BNP>250")
	(numeric_domain_term BNP)
	(operator %3E%3D)
	(unit "pg/ml")
	(value 250.0))

([ATHENA_HF_Class180001] of  Presence_Criterion

	(domain_term IF_NYHA_Class_II_III_IV_symptoms)
	(entry_type Note_Entry)
	(label "IF NHYA Class II or Class III or Class IV symptoms")
	(presence TRUE))

([ATHENA_HF_Class180002] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class180001]
		[ATHENA_HF_Class133535]
		[ATHENA_HF_Class170000])
	(label "LVEF <=35 & HF & (IF NYHA Class II or III or IV symptoms) & (creatinine low or egfr>30) & K<5")
	(operator AND))

([ATHENA_HF_Class180005] of  Drug_Usage

	(Absolute_Contraindications
		Female+and+most+recent+creatinine++%3E2
		Male+and+most+recent+creatinine%3E2.5
		Acitve+prescription+for+ACE+and+ARB
		Renal_Insufficiency
		K%3E5.0
		eGFR%3C30)
	(collateral_actions [ATHENA_HF_Class250001])
	(Compelling_Indications
		HF_and_LVEF%3C%3D35_and_NYHA_Class_III_IV_or_Class_II_and_elevated_BNP
		HF_and_LVEF_le_40_and_NYHA_II_III_IIV_or_DM)
	(Drug_Class_Name aldosterone+antagonist)
	(label "Aldosterone antagonist Astronaut II"))

([ATHENA_HF_Class190000] of  On_Screen_Message

	(label "elevated BNP")
	(message "Although lower values of BNP or NT-proBNP exclude the presence of HF and higher values have\nreasonably high positive predictive value to diagnose HF, elevated plasma levels\nfor both natriuretic peptides have been associated with a wide variety of cardiac (ACS, heart muscle disease, valvular heart disease, pericardial disease, atrial fibrilation, myocarditis, cardiac surgery, cardioverion) and noncardiac causes (advancing age, anemia, renal failure, obstuctive sleep apnea, severe pnemonia, pumonary hypertension, critical illness, bacterial sepsis, severe burns, toxic-metablic insults, including cancer chemotherapy and envenomation)..")
	(message_type Recommendation))

([ATHENA_HF_Class190001] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "NT pro BNP >=500")
	(numeric_domain_term NT_proBNP)
	(operator %3E%3D)
	(value 500.0))

([ATHENA_HF_Class190002] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "NT pro BNP>=750")
	(numeric_domain_term NT_proBNP)
	(operator %3E%3D)
	(unit "pg/ml")
	(value 750.0))

([ATHENA_HF_Class190003] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190001]
		[ATHENA_CKD_Instance_70005])
	(label "NT proBNP >=500 and male")
	(operator AND))

([ATHENA_HF_Class190004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190002]
		[ATHENA_CKD_Instance_40003])
	(label "NT proBNP>750 and female")
	(operator AND))

([ATHENA_HF_Class190005] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190003]
		[ATHENA_HF_Class190004])
	(label "NT proBNP>=750 & female or NT proBNP>=500 & male")
	(operator OR))

([ATHENA_HF_Class190006] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110005]
		[ATHENA_HF_Class200006]
		[ATHENA_HF_Class190010])
	(label "(IF NYHA Class III or IV) or (IF NYHA Class II and BNP elevated)")
	(operator OR))

([ATHENA_HF_Class190008] of  Presence_Criterion

	(domain_term IF_NHYA_Class_II_symptoms)
	(entry_type Note_Entry)
	(label "IF NYHA Class II symptoms")
	(presence TRUE))

([ATHENA_HF_Class190009] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class180000]
		[ATHENA_HF_Class190005])
	(label "BNP elevated or proBNP elevated")
	(operator OR))

([ATHENA_HF_Class190010] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190008]
		[ATHENA_HF_Class190009])
	(label "IF NYHA Class II symptoms and (BNP or NTproBNP elevated)")
	(operator AND))

([ATHENA_HF_Class190011] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class133535]
		[ATHENA_HF_Class170000]
		[ATHENA_HF_Class200010])
	(label "LVEF <=35 & HF & (IF NYHA Class III or IV symptoms or (NYHA II and elevated BNP)) & (creatinine low or egfr>30) & K<5")
	(operator AND))

([ATHENA_HF_Class190013] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class133535]
		[ATHENA_HF_Class170000]
		[ATHENA_HF_Class200004]
		[ATHENA_HF_Class30004])
	(label "LVEF <=35 & HF & (NYHA Class III or IV symptoms or (NYHA II and elevated BNP)) & (creatinine low or egfr>30) & K<5")
	(operator AND))

([ATHENA_HF_Class190014] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190009]
		[ATHENA_HF_Class190015])
	(label "NYHA Class II and (BNP or NTproBNP elevated)")
	(operator AND))

([ATHENA_HF_Class190015] of  Presence_Criterion

	(domain_term NYHA+functional+class+II)
	(entry_type Note_Entry)
	(label "Presence of NYHA Class II symptoms")
	(presence TRUE))

([ATHENA_HF_Class190017] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110015]
		[ATHENA_HF_Class190014])
	(label "(NYHA Class III or IV) or (Class II and elevated BNP or NTproBNP)")
	(operator OR))

([ATHENA_HF_Class2] of  Scenario

	(consultation_template [ATHENA_HF_Class50000])
	(followed_by [ATHENA_HF_Class60068])
	(label "Stage A HF")
	(new_encounter TRUE)
	(precondition [ATHENA_HF_Class10008]))

([ATHENA_HF_Class20000] of  Followed_By

	(%3AFROM [ATHENA_HF_Class2])
	(%3ATO [ATHENA_HF_Class60068]))

([ATHENA_HF_Class200000] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "ACE Inhibitor contraindicated")
	(PAL_constraint [ATHENA_HF_Class200017]))

([ATHENA_HF_Class200001] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class200000])
	(label "ACE-I or contraindication to ACE I")
	(operator OR))

([ATHENA_HF_Class200002] of  Presence_Criterion

	(domain_term prior_cardiovascular_hospitalization)
	(entry_type Note_Entry)
	(label "Presence of prior cardiovascular hospitalization")
	(presence TRUE))

([ATHENA_HF_Class200003] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190009]
		[ATHENA_HF_Class200002])
	(label "Prior cardiovascular hospitalization OR elevated BNP or elevated NTproBNP")
	(operator OR))

([ATHENA_HF_Class200004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110015]
		[ATHENA_HF_Class200005])
	(label "(NYHA Class III or IV) or (Class II and elevated BNP or NTproBNP or prior cardiovascular hospitalization)")
	(operator OR))

([ATHENA_HF_Class200005] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190015]
		[ATHENA_HF_Class200003])
	(label "NYHA Class II and (BNP or NTproBNP elevated or prior cardiovascular hospitalization)")
	(operator AND))

([ATHENA_HF_Class200006] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190008]
		[ATHENA_HF_Class200003])
	(label "IF NYHA Class II symptoms and (BNP or NTproBNP elevated or prior cardiovascular hospitalization)")
	(operator AND))

([ATHENA_HF_Class200007] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class133535]
		[ATHENA_HF_Class170000]
		[ATHENA_HF_Class200004])
	(label "LVEF <=35 & HF & (NYHA Class III or IV symptoms or (NYHA II and (elevated BNP or cardiovas hosptilaization)) & (creatinine low or egfr>30) & K<5")
	(operator AND))

([ATHENA_HF_Class200008] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class133535]
		[ATHENA_HF_Class170000]
		[ATHENA_HF_Class190006])
	(label "LVEF <=35 & HF & (IF NYHA Class III or IV symptoms or (NYHA II and elevated BNP or prior cardiovas hosp)) & (creatinine low or egfr>30) & K<5")
	(operator AND))

([ATHENA_HF_Class20001] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class40003])
	(label "Not_on_ACEI_ARB or BB")
	(operator OR))

([ATHENA_HF_Class200010] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110005]
		[ATHENA_HF_Class200006])
	(label "(IF NYHA Class III or IV) or (IF NYHA Class II and BNP elevated or prior cardiocascular hospitalizaiton)")
	(operator OR))

([ATHENA_HF_Class200011] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class200016])
	(label "BNP lab?")
	(rule_in [ATHENA_HF_Class200015]))

([ATHENA_HF_Class200012] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class170006])
	(%3ATO [ATHENA_HF_Class200011]))

([ATHENA_HF_Class200013] of  Presence_Criterion

	(domain_term BNP)
	(entry_type Numeric_Entry)
	(label "Absence of BNP lab in past 6 months")
	(period [library_Class30029])
	(presence FALSE))

([ATHENA_HF_Class200014] of  Presence_Criterion

	(domain_term NT_proBNP)
	(entry_type Numeric_Entry)
	(label "Absence of NT-ProBNP lab in past 6 months")
	(period [library_Class30029])
	(presence FALSE))

([ATHENA_HF_Class200015] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class200013]
		[ATHENA_HF_Class200014])
	(label "Absence of BNP and Absence of NTproBNP in last 6 months")
	(operator AND))

([ATHENA_HF_Class200016] of  On_Screen_Message

	(label "Order BNP or NTproBNP lab")
	(message "BNP and NTproBNP lab values absent.  Either of these measurements is useful in clinical decision making in HF.  Please order BNP or NTproBNP. [Level of Evidence A]")
	(message_type Recommendation))

([ATHENA_HF_Class200017] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "ACE Inhibitor contraindicated")
	(%3APAL-RANGE "(defrange ?condition :FRAME Note_Entry)\n(defrange ?problem :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_problem :FRAME Diagnostic_Term_Metaclass)\n(defrange ?drug_usage :FRAME Drug_Usage)")
	(%3APAL-STATEMENT "(forall ?drug_usage\n        (=> (Drug_Class_Name ?drug_usage ACE_Inhibitors)\n            (or (exists ?condition \n                        (and (patient_id ?condition $patient_id)\n                             (exists ?problem \n                                     (and (Absolute_Contraindications ?drug_usage ?problem)\n                                          (isa-classname (domain_term ?condition))\n                                          (or (= (coerce-to-class (domain_term ?condition)) ?problem )\n                                              (subclass-of (coerce-to-class (domain_term ?condition)) ?problem )) \n                                     ))))\n                (exists  ?derived_problem \n                         (and (Absolute_Contraindications ?drug_usage ?derived_problem)\n                              (is-derivable ?derived_problem))))\n        )\n)\n "))

([ATHENA_HF_Class20004] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "LVEF < 40")
	(numeric_domain_term Left+Ventricular+Ejection+fraction)
	(operator %3C)
	(value 40.0))

([ATHENA_HF_Class20005] of  Presence_Criterion

	(domain_term Prior_Myocardial_Infarction)
	(entry_type Note_Entry)
	(label "Prior Myocardial_Infarction")
	(presence TRUE))

([ATHENA_HF_Class20006] of  Presence_Criterion

	(domain_term Severe_LVH)
	(entry_type Note_Entry)
	(label "Severe LVH")
	(presence TRUE))

([ATHENA_HF_Class20008] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class10007])
	(label "Not Structural Heart Disease")
	(operator NOT))

([ATHENA_HF_Class210000] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "BB Stage C with MI contraindicated")
	(PAL_constraint [ATHENA_HF_Class210010]))

([ATHENA_HF_Class210001] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "BB Stage C no MI contraindicated")
	(PAL_constraint [ATHENA_HF_Class210011]))

([ATHENA_HF_Class210002] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "ARB contraindicated")
	(%3APAL-RANGE "(defrange ?condition :FRAME Note_Entry)\n(defrange ?problem :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_problem :FRAME Diagnostic_Term_Metaclass)\n(defrange ?drug_usage :FRAME Drug_Usage)")
	(%3APAL-STATEMENT "(forall ?drug_usage\n        (=> (Drug_Class_Name ?drug_usage Angiotensin_II_receptor_blockers)\n            (or (exists ?condition \n                        (and (patient_id ?condition $patient_id)\n                             (exists ?problem \n                                     (and (Absolute_Contraindications ?drug_usage ?problem)\n                                          (isa-classname (domain_term ?condition))\n                                          (or (= (coerce-to-class (domain_term ?condition)) ?problem )\n                                              (subclass-of (coerce-to-class (domain_term ?condition)) ?problem )) \n                                     ))))\n                (exists  ?derived_problem \n                         (and (Absolute_Contraindications ?drug_usage ?derived_problem)\n                              (is-derivable ?derived_problem))))\n        )\n)\n "))

([ATHENA_HF_Class210003] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "ARB contraindicated")
	(PAL_constraint [ATHENA_HF_Class210002]))

([ATHENA_HF_Class210004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50026]
		[ATHENA_HF_Class210003])
	(label "ARB or ARB contraindicated")
	(operator OR))

([ATHENA_HF_Class210005] of  Presence_Criterion

	(domain_term ACE_Inhibitors)
	(entry_type Medication)
	(label "Absence of ACE Inhibitor")
	(presence FALSE))

([ATHENA_HF_Class210006] of  Presence_Criterion

	(domain_term Angiotensin_II_receptor_blockers)
	(entry_type Medication)
	(label "Absence of ARB")
	(presence FALSE))

([ATHENA_HF_Class210007] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class210005]
		[ATHENA_HF_Class210006])
	(label "Absence of ACE-I or Absence of ARB")
	(operator OR))

([ATHENA_HF_Class210008] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class220006]
		[ATHENA_HF_Class220005])
	(label "ACE or ARB or contraindication and not both AND BB or contra to BB")
	(operator AND))

([ATHENA_HF_Class210009] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class200001]
		[ATHENA_HF_Class210004])
	(label "ACE or ARB or contraindication")
	(operator OR))

([ATHENA_HF_Class210010] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "BB Stage C w MI contraindicated")
	(%3APAL-RANGE "(defrange ?condition :FRAME Note_Entry)\n(defrange ?problem :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_problem :FRAME Diagnostic_Term_Metaclass)\n(defrange ?drug_usage :FRAME Drug_Usage)")
	(%3APAL-STATEMENT "(forall ?drug_usage\n        (=> (Drug_Class_Name ?drug_usage 'carvedilol')\n            (or (exists ?condition \n                        (and (patient_id ?condition $patient_id)\n                             (exists ?problem \n                                     (and (Absolute_Contraindications ?drug_usage ?problem)\n                                          (isa-classname (domain_term ?condition))\n                                          (or (= (coerce-to-class (domain_term ?condition)) ?problem )\n                                              (subclass-of (coerce-to-class (domain_term ?condition)) ?problem )) \n                                     ))))\n                (exists  ?derived_problem \n                         (and (Absolute_Contraindications ?drug_usage ?derived_problem)\n                              (is-derivable ?derived_problem))))\n        )\n)\n "))

([ATHENA_HF_Class210011] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "BB Stage C no MI contraindicated")
	(%3APAL-RANGE "(defrange ?condition :FRAME Note_Entry)\n(defrange ?problem :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_problem :FRAME Diagnostic_Term_Metaclass)\n(defrange ?drug_usage :FRAME Drug_Usage)")
	(%3APAL-STATEMENT "(forall ?drug_usage\n        (=> (Drug_Class_Name ?drug_usage 'Beta_Blocker Stage C Heart Failure')\n            (or (exists ?condition \n                        (and (patient_id ?condition $patient_id)\n                             (exists ?problem \n                                     (and (Absolute_Contraindications ?drug_usage ?problem)\n                                          (isa-classname (domain_term ?condition))\n                                          (or (= (coerce-to-class (domain_term ?condition)) ?problem )\n                                              (subclass-of (coerce-to-class (domain_term ?condition)) ?problem )) \n                                     ))))\n                (exists  ?derived_problem \n                         (and (Absolute_Contraindications ?drug_usage ?derived_problem)\n                              (is-derivable ?derived_problem))))\n        )\n)"))

([ATHENA_HF_Class220000] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class210001]
		[ATHENA_HF_Class210000])
	(label "BB Stage C contraindicated")
	(operator OR))

([ATHENA_HF_Class220002] of  Presence_Criterion

	(domain_term Beta_Blocker+Stage+C+Heart+Failure)
	(entry_type Medication)
	(label "Presence of Stage C BB no MI")
	(presence TRUE))

([ATHENA_HF_Class220003] of  Presence_Criterion

	(domain_term carvedilol)
	(entry_type Medication)
	(label "Presence of Stage C BB w MI")
	(presence TRUE))

([ATHENA_HF_Class220004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class220002]
		[ATHENA_HF_Class220003])
	(label "Presence of Stage C BB")
	(operator OR))

([ATHENA_HF_Class220005] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class220004]
		[ATHENA_HF_Class210001]
		[ATHENA_HF_Class210000])
	(label "Presence of Stage C BB or contraindication to BB")
	(operator OR))

([ATHENA_HF_Class220006] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class210009]
		[ATHENA_HF_Class210007])
	(label "ACE or ARB or contraindication and not both")
	(operator AND))

([ATHENA_HF_Class220007] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "Aldosterone_antagonist_contraindicated")
	(%3APAL-RANGE "(defrange ?condition :FRAME Note_Entry)\n(defrange ?problem :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_problem :FRAME Diagnostic_Term_Metaclass)\n(defrange ?drug_usage :FRAME Drug_Usage)")
	(%3APAL-STATEMENT "(forall ?drug_usage\n        (=> (Drug_Class_Name ?drug_usage 'aldosterone antagonist')\n            (or (exists ?condition \n                        (and (patient_id ?condition $patient_id)\n                             (exists ?problem \n                                     (and (Absolute_Contraindications ?drug_usage ?problem)\n                                          (isa-classname (domain_term ?condition))\n                                          (or (= (coerce-to-class (domain_term ?condition)) ?problem )\n                                              (subclass-of (coerce-to-class (domain_term ?condition)) ?problem )) \n                                     ))))\n                (exists  ?derived_problem \n                         (and (Absolute_Contraindications ?drug_usage ?derived_problem)\n                              (is-derivable ?derived_problem))))\n        )\n)"))

([ATHENA_HF_Class220008] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "hydralazine_and_nitrates_contraindicated")
	(%3APAL-RANGE "(defrange ?condition :FRAME Note_Entry)\n(defrange ?problem :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_problem :FRAME Diagnostic_Term_Metaclass)\n(defrange ?drug_usage :FRAME Drug_Usage)")
	(%3APAL-STATEMENT "(forall ?drug_usage\n        (=> (Drug_Class_Name ?drug_usage Hydralazine_and_nitrates)\n            (or (exists ?condition \n                        (and (patient_id ?condition $patient_id)\n                             (exists ?problem \n                                     (and (Absolute_Contraindications ?drug_usage ?problem)\n                                          (isa-classname (domain_term ?condition))\n                                          (or (= (coerce-to-class (domain_term ?condition)) ?problem )\n                                              (subclass-of (coerce-to-class (domain_term ?condition)) ?problem )) \n                                     ))))\n                (exists  ?derived_problem \n                         (and (Absolute_Contraindications ?drug_usage ?derived_problem)\n                              (is-derivable ?derived_problem))))\n        )\n)\n "))

([ATHENA_HF_Class220009] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "Aldosterone antagonist contraindicated")
	(PAL_constraint [ATHENA_HF_Class220007]))

([ATHENA_HF_Class220010] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "hydralazine and nitrates contraindicated")
	(PAL_constraint [ATHENA_HF_Class220008]))

([ATHENA_HF_Class220011] of  Presence_Criterion

	(domain_term Hydralazine_and_nitrates)
	(entry_type Medication)
	(label "Presence of hydralazine and nitrates")
	(presence TRUE))

([ATHENA_HF_Class220012] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110825]
		[ATHENA_HF_Class220009])
	(label "Aldosterone antagonist or contraindication to aldosterone antagonist")
	(operator OR))

([ATHENA_HF_Class220013] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class220011]
		[ATHENA_HF_Class220010])
	(label "Hydralazine_and_nitrates or contraindication to hydralazine_and_nitrates")
	(operator OR))

([ATHENA_HF_Class220014] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190015]
		[ATHENA_HF_Class110016]
		[ATHENA_HF_Class110017])
	(label "Presence of NYHA Class II III or IV symptoms")
	(operator OR))

([ATHENA_HF_Class220015] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class220014])
	(label "NOT Presence of NYHA II III IV symptoms")
	(operator NOT))

([ATHENA_HF_Class220016] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class220012]
		[ATHENA_HF_Class220013]
		[ATHENA_HF_Class220015]
		[ATHENA_HF_Class122379]
		[ATHENA_HF_Class220022])
	(label "AA or contra OR hydralazine & nitrates or contra OR Loop diuretics or contra OR Absence class II III IV symptoms OR Presence NYHA class I symptoms")
	(operator OR))

([ATHENA_HF_Class220017] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class210008]
		[ATHENA_HF_Class220016])
	(label "GDMT")
	(operator AND))

([ATHENA_HF_Class220018] of  Drug_Usage

	(Drug_Class_Name Loop_diuretics)
	(label "Loop diuretic Astronaut"))

([ATHENA_HF_Class220019] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "Loop_diuretic_contraindicated")
	(%3APAL-RANGE "(defrange ?condition :FRAME Note_Entry)\n(defrange ?problem :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_problem :FRAME Diagnostic_Term_Metaclass)\n(defrange ?drug_usage :FRAME Drug_Usage)")
	(%3APAL-STATEMENT "(forall ?drug_usage\n        (=> (Drug_Class_Name ?drug_usage Loop_diuretics)\n            (or (exists ?condition \n                        (and (patient_id ?condition $patient_id)\n                             (exists ?problem \n                                     (and (Absolute_Contraindications ?drug_usage ?problem)\n                                          (isa-classname (domain_term ?condition))\n                                          (or (= (coerce-to-class (domain_term ?condition)) ?problem )\n                                              (subclass-of (coerce-to-class (domain_term ?condition)) ?problem )) \n                                     ))))\n                (exists  ?derived_problem \n                         (and (Absolute_Contraindications ?drug_usage ?derived_problem)\n                              (is-derivable ?derived_problem))))\n        )\n)"))

([ATHENA_HF_Class220020] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "Loop diuretic contraindicated")
	(PAL_constraint [ATHENA_HF_Class220019]))

([ATHENA_HF_Class220021] of  Presence_Criterion

	(domain_term Loop_diuretics)
	(entry_type Medication)
	(label "Presence of loop_diuretics")
	(presence TRUE))

([ATHENA_HF_Class220022] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class220021]
		[ATHENA_HF_Class220020])
	(label "Presence of loop diuretic or contraindication to loop diuretic")
	(operator OR))

([ATHENA_HF_Class230000] of  Presence_Criterion

	(domain_term Left_Bundle_Branch_Block)
	(entry_type Note_Entry)
	(label "Presence of LBBB")
	(presence TRUE))

([ATHENA_HF_Class230001] of  Conditional_On_Screen_Message

	(label "ICD primary prev rec Stage C Astronaut II")
	(message "ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year (355, 593). (Level of Evidence:  A)")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class230002]))

([ATHENA_HF_Class230002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class161508]
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class220017]
		[ATHENA_HF_Class220014])
	(label "(MI 40 days old OR non-ischemid dilated cardiomyopathy) & LVEF le 35 & II III IV symptoms & GDMT")
	(operator AND))

([ATHENA_HF_Class230003] of  Conditional_On_Screen_Message

	(label "ICD primary prev rec Stage C stage I Astronaut II")
	(message "ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of30% or less, and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year (362, 597, 598). (Level of Evidence:  B)*")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class230004]))

([ATHENA_HF_Class230004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class161507]
		[ATHENA_HF_Class110349]
		[ATHENA_HF_Class122379]
		[ATHENA_HF_Class220017])
	(label "(MI 40 days old) AND LVEF<=30 AND NYHA I symptoms AND GDMT")
	(operator AND))

([ATHENA_HF_Class230005] of  Conditional_On_Screen_Message

	(label "CRT when LVEF<=35% and QRS>=0.15s and LBBB Astronaut II")
	(message "CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).  ALERT:  we assumed the presence of sinus rhythm, LBBB with QRS duration of >150ms.")
	(message_type Class+I)
	(rule_in_condition [KB_899077_Class0])
	(%3ADOCUMENTATION "removed rule-in criteria of sinus rhythm; qrs>.15; LBBB"))

([ATHENA_HF_Class230006] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class50049]
		[ATHENA_HF_Class220017]
		[ATHENA_HF_Class230009]
		[ATHENA_HF_Class240001])
	(label "LVEF<=35 & QRS >=0.15 & sinus rhythm & LBBB & NYHA functional class II or III or ambulatory class IV symptoms & GDMT")
	(operator AND))

([ATHENA_HF_Class230007] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "QRS >= .15")
	(numeric_domain_term QRS)
	(operator %3E%3D)
	(unit "s")
	(value 0.15))

([ATHENA_HF_Class230009] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class190015]
		[ATHENA_HF_Class110016]
		[ATHENA_HF_Class230010])
	(label "Presence of NYHA II III or ambulatory IV")
	(operator OR))

([ATHENA_HF_Class230010] of  Presence_Criterion

	(domain_term NYHA_functional_class_IV_ambulatory)
	(entry_type Note_Entry)
	(label "Presence NYHA IV ambulatory symptoms")
	(presence TRUE))

([ATHENA_HF_Class230011] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110016]
		[ATHENA_HF_Class230010])
	(label "Presencoe of NYHA III or ambulatory IV symptoms")
	(operator OR))

([ATHENA_HF_Class240000] of  On_Screen_Message

	(label "test")
	(message "test")
	(message_type Recommendation))

([ATHENA_HF_Class240001] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class230000]
		[ATHENA_HF_Class230007])
	(label "LBBB and QRS>=.15")
	(operator AND))

([ATHENA_HF_Class240002] of  Drug_Usage

	(collateral_actions [KB_899077_Class8])
	(Compelling_Indications HF+%28ICD+or+Symptoms%29+and+LVEF%3C%3D40+and+no+MI)
	(Drug_Class_Name Beta_Blocker+Stage+C+Heart+Failure)
	(formulary_preferred_drug_in_class
		[ATHENA_HF_Class50094]
		[ATHENA_HF_Class50092]
		[ATHENA_HF_Class50093])
	(label "Beta blocker Stage C HF no MI Astronaut II"))

([ATHENA_HF_Class240003] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50068]
		[ATHENA_HF_Class30004])
	(label "Stage C HF or ICD9 HF")
	(operator OR))

([ATHENA_HF_Class240004] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class240003]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50036]
		[ATHENA_HF_Class60072])
	(label "Stage C or ICD9 HF AND EF<=40 AND symptoms AND ADR ACE")
	(operator AND))

([ATHENA_HF_Class240006] of  Drug_Usage

	(Absolute_Contraindications
		Angioedema+due+to+ADR+to+ACEI
		Angioedema_due_to_ADR_to_ARB
		K%3E5
		Pregnancy)
	(collateral_actions [KB_899077_Class3])
	(Compelling_Indications
		No+HF%2C+MI%2C++LVEF%3C%3D40+and+ADR+ACE
		Stage+C+and+LVEF%3C%3D40+and+symptoms+and+ADR+ACE)
	(Drug_Class_Name Angiotensin_II_receptor_blockers)
	(label "ARB Astronaut II")
	(Relative_Contraindications
		20PercentIncreaseCreatinineACE_ARB
		CKD_Stage3or4_15eGFR_gt60
		CKD_stage_5_or_eGFR_lt15
		Prescription_Aliskiren
		Prescription_Ksparingdiuretic
		Prescription_NSAID
		Aortic_stenosis
		Renal_artery_stenosis
		Hypertrophic_cardiomyopathy)
	(Relative_Indications
		HTN+and+LVH
		Stage+B+and+LVEF%3C%3D40+and+ADR+ACE
		Mild-moderate+HF+symptoms+and+LVEF%3C%3D+40+and+ACE+intolerant
		High+Risk+for+HF+and+DM%2C+HTN%2C+or+atherosclerotic+vascular+disease
		HF+with+persistent+symptoms+and+LVEF%3C%3D40+and+treated+with+conventional+therapy)
	(%3ADOCUMENTATION "same as ARB, but compelling indication added symptoms"))

([ATHENA_HF_Class240007] of  Presence_Criterion

	(domain_term Myocardial_Infarction)
	(entry_type Note_Entry)
	(label "Presence of MI within last 6 mo")
	(period [ATHENA_HF_Class240008])
	(presence TRUE))

([ATHENA_HF_Class240008] of  Relative_Time_Interval_Definite

	(how_many "6")
	(label "6 months before today")
	(polarity Before)
	(relative_time_point [time%3AINSTANCE_1])
	(time_unit month))

([ATHENA_HF_Class240009] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class240007]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class240010]
		[ATHENA_HF_Class30004])
	(label "MI in last 6 months AND HF AND LVEF<=40 AND NYHA II III IV symptoms or DM")
	(operator AND))

([ATHENA_HF_Class240010] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class220014]
		[ATHENA_HF_Class240011])
	(label "NYHA II III IV or DM")
	(operator OR))

([ATHENA_HF_Class240011] of  Presence_Criterion

	(domain_term Diabetes_Mellitus)
	(entry_type Note_Entry)
	(label "Presence of DM")
	(presence TRUE))

([ATHENA_HF_Class240015] of  Collateral_Action

	(actions
		[ATHENA_HF_Class170329]
		[ATHENA_HF_Class110383])
	(label "add hydralazine and nitrates Astronaut II")
	(mood Recommend_Add))

([ATHENA_HF_Class240016] of  On_Screen_Message

	(label "rec add hyralazine_nitrates Astronaut II")
	(message "The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (423, 424). (Level of Evidence: A)")
	(message_type Class+I))

([ATHENA_HF_Class250000] of  Action_Choice

	(actions
		[ATHENA_HF_Class110823]
		[ATHENA_HF_Class170004])
	(label "Harmful to HF")
	(strict_rule_in_condition [ATHENA_HF_Class260002]))

([ATHENA_HF_Class250001] of  Collateral_Action

	(actions
		[ATHENA_HF_Class70167]
		[ATHENA_HF_Class110353]
		[KB_899077_Class5])
	(label "Add Aldosterone antagonist warning Astronaut")
	(mood Recommend_Add))

([ATHENA_HF_Class250282] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50026]
		[ATHENA_HF_Class50024])
	(label "Active prescription for ACE AND ARB")
	(operator AND))

([ATHENA_HF_Class260000] of  Drug_Usage

	(Absolute_Contraindications
		Pregnancy
		K%3E5
		Angioedema+due+to+ADR+to+ACEI
		Angioedema_due_to_ADR_to_ARB)
	(collateral_actions
		[ATHENA_HF_Class170010]
		[ATHENA_HF_Class170009]
		[KB_899077_Class1])
	(Compelling_Indications
		HF+%28ICD9+or+symptoms%29+and+LVEF%3C%3D40
		LVEF%3C%3D40+and+MI+or+ACS+Stage+B
		LVEF%3C%3D40+and+no+HF+symptoms)
	(Drug_Class_Name ACE_Inhibitors)
	(formulary_preferred_drug_in_class
		[ATHENA_HF_Class10001]
		[ATHENA_HF_Class50040]
		[ATHENA_HF_Class50042])
	(label "Ace_Inhibitor Astronaut II")
	(Relative_Contraindications
		Active+prescription+for+ARB+and+aldosterone+antagonist
		Aortic_stenosis
		Hypertrophic_cardiomyopathy
		Renal_artery_stenosis
		Prescription_Aliskiren
		Prescription_Ksparingdiuretic
		Prescription_NSAID
		CKD_Stage3or4_15eGFR_gt60
		CKD_stage_5_or_eGFR_lt15
		20PercentIncreaseCreatinineACE_ARB)
	(Relative_Indications
		HTN+and+LVH
		High+Risk+for+HF+and+DM%2C+HTN%2C+or+atherosclerotic+vascular+disease))

([ATHENA_HF_Class260001] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class250000]))

([ATHENA_HF_Class260002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class110824]
		[ATHENA_HF_Class170003])
	(label "Harmful drugs criteria")
	(operator OR))

([ATHENA_HF_Class260070] of  Presence_Criterion

	(domain_term THIAZOLIDINEDIONES)
	(entry_type Medication)
	(label "Presence of thiazolidinedione")
	(presence TRUE))

([ATHENA_HF_Class270000] of  Action_Choice

	(actions
		[ATHENA_HF_Class300008]
		[ATHENA_HF_Class160000]
		[ATHENA_HF_Class230003]
		[ATHENA_HF_Class230005]
		[ATHENA_HF_Class230001])
	(label "LCEF <=40 AND (SBP<110 OR high creatinine)")
	(strict_rule_in_condition [ATHENA_HF_Class300006]))

([ATHENA_HF_Class270001] of  Presence_Criterion

	(domain_term Acute_Coronary_Syndrome)
	(entry_type Note_Entry)
	(label "History of ACS")
	(presence TRUE))

([ATHENA_HF_Class270002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50011]
		[ATHENA_HF_Class270001])
	(label "Presence of MI or ACS")
	(operator OR))

([ATHENA_HF_Class270003] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class120002]
		[ATHENA_HF_Class270002]
		[ATHENA_HF_Class60053])
	(label "LVEF<=40 and MI or ACS Stage B")
	(operator AND))

([ATHENA_HF_Class270266] of  Presence_Criterion

	(domain_term aldosterone+antagonist)
	(entry_type Medication)
	(label "Absence of aldosterone antagonist")
	(presence FALSE))

([ATHENA_HF_Class280000] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class300001]
		[ATHENA_HF_Class300002])
	(label "LVEF<=40 and SBP>110 and creatinine<2.5 (men) and 2.3 (women)")
	(operator AND))

([ATHENA_HF_Class280001] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "Angioedema dure to ADR to ARB")
	(PAL_constraint [ATHENA_HF_Class280002]))

([ATHENA_HF_Class280002] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "Presence of angioedema due to ADR to ARB")
	(%3APAL-RANGE "(defrange ?reaction :FRAME Adverse_Reaction)")
	(%3APAL-STATEMENT "(exists ?reaction \n        (and (= (patient_id ?reaction) $patient_id) \n             (or (= (substance ?reaction) Angiotensin_II_receptor_blockers)\n                 ( subclass-of (substance ?reaction) Angiotensin_II_receptor_blockers))\n             (or (= (domain_term ?reaction) angioedema))\n        )\n)"))

([ATHENA_HF_Class280003] of  Diagnostic_Term_Metaclass
)

([ATHENA_HF_Class290000] of  PAL_Criterion

	(case_variable "$patient_id")
	(label "There exists a contraindicated current med w no complicating factor")
	(PAL_constraint [library_Class80000]))

([ATHENA_HF_Class290001] of  N_ary_Criterion

	(criteria
		[library_Class30002]
		[ATHENA_HF_Class290002])
	(label "SBP<110 OR (Creatinine>=2.5 (men) 2.3(women))")
	(operator OR))

([ATHENA_HF_Class290002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class290003]
		[ATHENA_HF_Class290005])
	(label "creatinine>=2.5 (men) or >=2.3 (women)")
	(operator OR))

([ATHENA_HF_Class290003] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00100]
		[ATHENA_HF_Class290004])
	(label "most recent creatinine >=2.3 and female")
	(operator AND))

([ATHENA_HF_Class290004] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "most recent creatinine >=2.3")
	(numeric_domain_term Creatinine)
	(operator %3E%3D)
	(value 2.3))

([ATHENA_HF_Class290005] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00102]
		[ATHENA_HF_Class290006])
	(label "most recent creatinine >=2.5 and male")
	(operator AND))

([ATHENA_HF_Class290006] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "most recent creatinine >=2.5")
	(numeric_domain_term Creatinine)
	(operator %3E%3D)
	(value 2.5))

([ATHENA_HF_Class30000] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class30001]
		[ATHENA_HF_Class10007])
	(label "Criteria for Stage C HF")
	(operator AND))

([ATHENA_HF_Class300000] of  Action_Choice

	(actions
		[ATHENA_HF_Class300008]
		[ATHENA_HF_Class160000]
		[ATHENA_HF_Class230003]
		[ATHENA_HF_Class230005]
		[ATHENA_HF_Class230001])
	(label "no contraindic med and LCEF <=40 AND (SBP<110 OR high creatinine)")
	(strict_rule_in_condition [ATHENA_HF_Class310003]))

([ATHENA_HF_Class300001] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "most recent SBP>=110")
	(numeric_domain_term Systolic_BP)
	(operator %3E%3D)
	(value 110.0))

([ATHENA_HF_Class300002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class300003]
		[ATHENA_HF_Class300004])
	(label "creatinine <2.5 (men) OR <2.3 (women)")
	(operator OR))

([ATHENA_HF_Class300003] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00102]
		[athena_hypertension_INSTANCE_00559])
	(label "most recent creatinine <2.5 and male")
	(operator AND))

([ATHENA_HF_Class300004] of  N_ary_Criterion

	(criteria
		[athena_hypertension_INSTANCE_00100]
		[ATHENA_HF_Class300005])
	(label "most recent creatinine <2.3 and female")
	(operator AND))

([ATHENA_HF_Class300005] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "most recent creatinine <2.3")
	(numeric_domain_term Creatinine)
	(operator %3C)
	(value 2.3))

([ATHENA_HF_Class300006] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class290001]
		[ATHENA_HF_Class50019])
	(label "LCEF <=40 AND (SBP<110 OR high creatinine)")
	(operator AND))

([ATHENA_HF_Class300007] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class270000]))

([ATHENA_HF_Class300008] of  Evaluate_Start_Activity

	(alternatives
		[ATHENA_HF_Class180005]
		[ATHENA_HF_Class240002]
		[ATHENA_HF_Class90000]
		[ATHENA_HF_Class110018])
	(label "Evaluate start activity SBP<110 or elevated creatinine Astronaut"))

([ATHENA_HF_Class30001] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class60072])
	(label "Symptoms of HF")
	(operator OR))

([ATHENA_HF_Class30002] of  Presence_Criterion

	(domain_term Beta-Blockers)
	(entry_type Medication)
	(label "Not_on_betablocker")
	(mood Authorized)
	(presence FALSE))

([ATHENA_HF_Class30004] of  Presence_Criterion

	(domain_term Heart_Failure)
	(entry_type Note_Entry)
	(label "Heart_Failure")
	(presence TRUE))

([ATHENA_HF_Class30005] of  Presence_Criterion

	(domain_term Heart_Failure)
	(entry_type Note_Entry)
	(label "Absence_Heart_Failure")
	(presence FALSE))

([ATHENA_HF_Class30009] of  Choice_Step

	(branches [ATHENA_HF_Class50009])
	(label "Secondary prevention"))

([ATHENA_HF_Class30016] of  Followed_By

	(%3AFROM [ATHENA_HF_Class10003])
	(%3ATO [ATHENA_HF_Class30009]))

([ATHENA_HF_Class30017] of  Action_Choice

	(actions [ATHENA_HF_Class70037])
	(label "stage A drug choices")
	(strict_rule_in_condition [ATHENA_HF_Class70036]))

([ATHENA_HF_Class30018] of  Drug_Usage

	(Compelling_Indications
		Stage+C+and+LVEF%3C%3D40+and+ADR+ACE
		No+HF%2C+MI%2C++LVEF%3C%3D40+and+ADR+ACE)
	(Drug_Class_Name Angiotensin_II_receptor_blockers)
	(label "ARB")
	(Relative_Contraindications Active+prescription+for+ACE+and+aldosterone+antagonists)
	(Relative_Indications
		HTN+and+LVH
		Stage+B+and+LVEF%3C%3D40+and+ADR+ACE
		Mild-moderate+HF+symptoms+and+LVEF%3C%3D+40+and+ACE+intolerant
		High+Risk+for+HF+and+DM%2C+HTN%2C+or+atherosclerotic+vascular+disease
		HF+with+persistent+symptoms+and+LVEF%3C%3D40+and+treated+with+conventional+therapy)
	(%3ADOCUMENTATION "StageC=ICD9 code AND assumes current or prior symptoms"))

([ATHENA_HF_Class310000] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class270000]))

([ATHENA_HF_Class310001] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class290000])
	(label "NOT There exists a contraindicated current med w no complicating factor")
	(operator NOT))

([ATHENA_HF_Class310002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class300001]
		[ATHENA_HF_Class300002]
		[ATHENA_HF_Class310001])
	(label "no contraindic med and LVEF<=40 and SBP>110 and creatinine<2.5 (men) and 2.3 (women)")
	(operator AND))

([ATHENA_HF_Class310003] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class290001]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class310001])
	(label "no contraindc med and LCEF <=40 AND (SBP<110 OR high creatinine)")
	(operator AND))

([ATHENA_HF_Class320001] of  Action_Choice

	(actions
		[ATHENA_HF_Class101051]
		[ATHENA_HF_Class160002]
		[ATHENA_HF_Class230001]
		[ATHENA_HF_Class230003]
		[ATHENA_HF_Class230005])
	(label "Stage C HF rec LVEF <= 40 and no contraindic cur med")
	(strict_rule_in_condition [ATHENA_HF_Class310003]))

([ATHENA_HF_Class320002] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class300000]))

([ATHENA_HF_Class320003] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class320001]))

([ATHENA_HF_Class330001] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class130004]))

([ATHENA_HF_Class330002] of  Action_Choice

	(actions [ATHENA_HF_Class330003])
	(label "Presence of contraindication, Stop")
	(strict_rule_in_condition [ATHENA_Lipid_Class160247]))

([ATHENA_HF_Class330003] of  Evaluate_Stop_Activity

	(activity_class "Medication")
	(activity_spec Drug_Usage)
	(activity_spec_key [Drug_Class_Name])
	(activity_to_stop [athena_hypertension_495106])
	(domain_term Anti-Hypertensive_Drugs_Inclusive)
	(label "Stop contraindicated drug"))

([ATHENA_HF_Class330004] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [ATHENA_HF_Class330002]))

([ATHENA_HF_Class340248] of  Action_Choice

	(actions
		[athena_edit_138532]
		[ATHENA_HF_Class340251]
		[KB_899077_Class2])
	(label "Absence of ACE-I, add ACE-I")
	(strict_rule_in_condition [ATHENA_HF_Class210005]))

([ATHENA_HF_Class340249] of  Scenario

	(consultation_template [ATHENA_HF_Class170005])
	(followed_by [ATHENA_HF_Class340250])
	(label "All patients")
	(new_encounter TRUE)
	(precondition [criterion_INSTANCE_00001]))

([ATHENA_HF_Class340250] of  Choice_Step

	(branches [ATHENA_HF_Class340248])
	(label "All patient choices"))

([ATHENA_HF_Class340251] of  On_Screen_Message

	(label "Absence of ACE-I, add ACE-I")
	(message "Patient is not taking ACE-I; add ACE-I.")
	(message_type Primary_Recommendation))

([ATHENA_HF_Class350555] of  Followed_By

	(%3AFROM [ATHENA_HF_Class340249])
	(%3ATO [ATHENA_HF_Class340250]))

([ATHENA_HF_Class350556] of  Followed_By

	(%3AFROM [ATHENA_HF_Class340250])
	(%3ATO [ATHENA_HF_Class340248]))

([ATHENA_HF_Class40000] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class70168]
		[ATHENA_HF_Class150004]
		[athena_hypertension_360026])
	(label "African American & (IF moderate or severe symptoms) & using ACE & BB")
	(operator AND))

([ATHENA_HF_Class40002] of  Presence_Criterion

	(domain_term fatigue)
	(entry_type Note_Entry)
	(label "Presence of fatigue")
	(presence TRUE))

([ATHENA_HF_Class40003] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class40005]
		[ATHENA_HF_Class50004])
	(label "Not on ACEI or ARB")
	(operator OR))

([ATHENA_HF_Class40005] of  Presence_Criterion

	(domain_term ACE_Inhibitors)
	(entry_type Medication)
	(label "Not_on_ACEI")
	(mood Authorized)
	(presence FALSE))

([ATHENA_HF_Class40006] of  Start_Activity

	(activity [ATHENA_HF_Class10000])
	(label "Prescribe_ACEI"))

([ATHENA_HF_Class50000] of  Consultation_Guideline

	(first_step [ATHENA_HF_Class50001])
	(label "Stage A consultation messages")
	(steps
		[ATHENA_HF_Class50001]
		[ATHENA_HF_Class50002]
		[ATHENA_HF_Class50003]
		[ATHENA_HF_Class60006]
		[ATHENA_HF_Class60007]
		[ATHENA_HF_Class70008]
		[ATHENA_HF_Class70009]
		[ATHENA_HF_Class70010]
		[ATHENA_HF_Class70011]
		[ATHENA_HF_Class70012]
		[ATHENA_HF_Class110411])
	(transitions
		[ATHENA_HF_Class60004]
		[ATHENA_HF_Class60005]
		[ATHENA_HF_Class70013]
		[ATHENA_HF_Class70014]
		[ATHENA_HF_Class70015]
		[ATHENA_HF_Class70016]
		[ATHENA_HF_Class70017]
		[ATHENA_HF_Class70018]
		[ATHENA_HF_Class70019]
		[ATHENA_HF_Class110413]))

([ATHENA_HF_Class50001] of  Consultation_Branch_Step

	(branches
		[ATHENA_HF_Class50002]
		[ATHENA_HF_Class50003]
		[ATHENA_HF_Class70009]
		[ATHENA_HF_Class60006]
		[ATHENA_HF_Class70008]
		[ATHENA_HF_Class60007]
		[ATHENA_HF_Class70010]
		[ATHENA_HF_Class70012]
		[ATHENA_HF_Class70011]
		[ATHENA_HF_Class110411])
	(label "Stage A messages")
	(selection_method all_of))

([ATHENA_HF_Class50002] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70020])
	(label "Hypertension control")
	(rule_in [ATHENA_HF_Class70029])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class50003] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70021])
	(label "Lipid disorder control")
	(rule_in [ATHENA_HF_Class70031])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class50004] of  Presence_Criterion

	(domain_term Angiotensin_II_receptor_blockers)
	(entry_type Medication)
	(label "Not on ARB")
	(mood Authorized)
	(presence FALSE))

([ATHENA_HF_Class50007] of  Evaluate_Start_Activity

	(label "Add Beta Blocker"))

([ATHENA_HF_Class50008] of  Start_Activity

	(label "Add Beta blocker"))

([ATHENA_HF_Class50009] of  Action_Choice

	(actions
		[ATHENA_HF_Class50051]
		[ATHENA_HF_Class50061]
		[ATHENA_HF_Class50052]
		[ATHENA_HF_Class50058]
		[ATHENA_HF_Class50062]
		[ATHENA_HF_Class50065]
		[ATHENA_HF_Class120883]
		[ATHENA_HF_Class110348]
		[ATHENA_HF_Class110350])
	(label "Stage B HF action")
	(strict_rule_in_condition [criterion_INSTANCE_00001]))

([ATHENA_HF_Class50011] of  Presence_Criterion

	(domain_term Myocardial_Infarction)
	(entry_type Note_Entry)
	(label "Presence of MI")
	(presence TRUE))

([ATHENA_HF_Class50012] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50011]
		[ATHENA_HF_Class40003])
	(label "Previous MI and no ACEI (or ARB)")
	(operator AND))

([ATHENA_HF_Class50013] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50011]
		[ATHENA_HF_Class30002])
	(label "Previous MI and no beta blocker")
	(operator AND))

([ATHENA_HF_Class50014] of  Followed_By

	(%3AFROM [ATHENA_HF_Class30009])
	(%3ATO [ATHENA_HF_Class50009]))

([ATHENA_HF_Class50017] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50018]
		[ATHENA_HF_Class50019])
	(label "LVEF < 35 (?) and no MI")
	(operator AND))

([ATHENA_HF_Class50018] of  Presence_Criterion

	(domain_term Myocardial_Infarction)
	(entry_type Note_Entry)
	(label "Absence of MI")
	(presence FALSE))

([ATHENA_HF_Class50019] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "LVEF <= 40")
	(numeric_domain_term Left+Ventricular+Ejection+fraction)
	(operator %3C%3D)
	(value 40.0))

([ATHENA_HF_Class50020] of  Presence_Criterion

	(domain_term Beta-Blockers)
	(entry_type Medication)
	(label "Absence of beta blocker")
	(mood Authorized)
	(presence FALSE))

([ATHENA_HF_Class50024] of  Presence_Criterion

	(domain_term ACE_Inhibitors)
	(entry_type Medication)
	(label "Presence of ACE Inhibitor")
	(mood Authorized)
	(presence TRUE))

([ATHENA_HF_Class50025] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class50026])
	(label "Presence of ACEI or ARB")
	(operator OR))

([ATHENA_HF_Class50026] of  Presence_Criterion

	(domain_term Angiotensin_II_receptor_blockers)
	(entry_type Medication)
	(label "Presence of ARB")
	(mood Authorized)
	(presence TRUE))

([ATHENA_HF_Class50030] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50031]
		[ATHENA_HF_Class50032])
	(label "HTN and LVH")
	(operator AND))

([ATHENA_HF_Class50031] of  Presence_Criterion

	(domain_term Hypertension_Inclusive)
	(entry_type Note_Entry)
	(label "Presence of hypertension")
	(presence TRUE))

([ATHENA_HF_Class50032] of  Presence_Criterion

	(domain_term LVH)
	(entry_type Note_Entry)
	(label "Presence of LVH")
	(presence TRUE))

([ATHENA_HF_Class50035] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50011]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50036]
		[ATHENA_HF_Class60088]
		[ATHENA_HF_Class60054])
	(label "NO HF, MI, LVEF<=40 and ADR ACE")
	(operator AND))

([ATHENA_HF_Class50036] of  Presence_Criterion

	(domain_term ACE_Inhibitors)
	(entry_type Adverse_Reaction)
	(label "Adverse Reaction to ACEI")
	(presence TRUE))

([ATHENA_HF_Class50037] of  Drug_Usage

	(collateral_actions [ATHENA_HF_Class110360])
	(Compelling_Indications
		Myocardial_Infarction
		LVEF%3C%3D40+and+no+HF+symptoms
		HF+%28ICD9+or+symptoms%29+and+LVEF%3C%3D40)
	(Drug_Class_Name Beta-Blockers)
	(formulary_preferred_drug_in_class
		[ATHENA_HF_Class50092]
		[ATHENA_HF_Class50093]
		[ATHENA_HF_Class50094])
	(label "Beta Blocker"))

([ATHENA_HF_Class50039] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50036])
	(label "LVEF <=40 and intolerant ACE")
	(operator AND))

([ATHENA_HF_Class50040] of  Guideline_Drug

	(collateral_actions
		[ATHENA_HF_Class110354]
		[ATHENA_HF_Class110359])
	(dose_level_ranges [ATHENA_HF_Class50041])
	(drug_usage [ATHENA_HF_Class10000])
	(generic_drug lisinopril)
	(label "Lisinopril")
	(max_recommended_dose_level High_Dose%28high%2Flow%29)
	(rule_in [ATHENA_HF_Class50011])
	(starting_dose 2.5))

([ATHENA_HF_Class50041] of  Range_Mapping_Entry

	(abstract_value High_Dose%28high%2Flow%29)
	(lower_limit 2.5)
	(upper_limit 20.0))

([ATHENA_HF_Class50042] of  Guideline_Drug

	(collateral_actions
		[ATHENA_HF_Class110356]
		[ATHENA_HF_Class110358])
	(dose_level_ranges [ATHENA_HF_Class50044])
	(generic_drug enalapril)
	(label "Enalapril")
	(max_recommended_dose_level High_Dose%28high%2Flow%29)
	(rule_in [ATHENA_HF_Class50043])
	(starting_dose 5.0))

([ATHENA_HF_Class50043] of  Presence_Criterion

	(domain_term Heart_Failure)
	(entry_type Note_Entry)
	(label "Presence of HF")
	(presence TRUE))

([ATHENA_HF_Class50044] of  Range_Mapping_Entry

	(abstract_value High_Dose%28high%2Flow%29)
	(lower_limit 5.0)
	(upper_limit 20.0))

([ATHENA_HF_Class50045] of  Drug_Usage

	(Absolute_Contraindications
		Heart_Failure
		LVEF%3C%3D40+and+no+HF+symptoms
		Myocardial_Infarction
		HF+%28ICD9+or+symptoms%29+and+LVEF%3C%3D40)
	(Drug_Class_Name Non-Dihydropyridines)
	(label "NDHP CCB"))

([ATHENA_HF_Class50046] of  Drug_Usage

	(Absolute_Contraindications LVEF%3C%3D40+and+sinus+rhythm+and+Stage+B+and+absence+HF+symptoms)
	(collateral_actions [ATHENA_HF_Class110370])
	(Drug_Class_Name digoxin)
	(label "Digoxin")
	(Relative_Indications HF+%28ICD9+or+symptoms%29+and+LVEF%3C%3D40))

([ATHENA_HF_Class50048] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50049]
		[ATHENA_HF_Class10007]
		[ATHENA_HF_Class60054]
		[ATHENA_HF_Class60088])
	(label "LVEF<=40 and sinus shythm and Stage B and absence HF symptoms")
	(operator AND))

([ATHENA_HF_Class50049] of  Presence_Criterion

	(domain_term sinus+rhythm)
	(entry_type Note_Entry)
	(label "sinus rhythm")
	(presence TRUE))

([ATHENA_HF_Class50050] of  Presence_Criterion

	(domain_term Stage+B+Heart+Failure)
	(entry_type Note_Entry)
	(label "Stage B HF")
	(presence TRUE))

([ATHENA_HF_Class50051] of  Evaluate_Start_Activity

	(alternatives
		[ATHENA_HF_Class10000]
		[ATHENA_HF_Class30018]
		[ATHENA_HF_Class50046]
		[ATHENA_HF_Class50045]
		[ATHENA_HF_Class70001]
		[ATHENA_HF_Class80000])
	(label "Evaluate drugs for stage B HF"))

([ATHENA_HF_Class50052] of  Conditional_On_Screen_Message

	(label "Refer cardiology for ICD (ischemic cardiomyopathy)")
	(message "Placement of an ICD is reasonable in patients with ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF of 30% or less, are NYHA functional class I on chronic optimal medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. \nIf this is the case, refer to cardiology.")
	(message_type Class+II+a)
	(rule_in_condition [ATHENA_HF_Class50053]))

([ATHENA_HF_Class50053] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50054]
		[ATHENA_HF_Class50055]
		[ATHENA_HF_Class90384]
		[ATHENA_HF_Class122379]
		[ATHENA_HF_Class50011])
	(label "ischemic heart disease and LVEF<=30 and >40d postMI and NYHA functional class I")
	(operator AND))

([ATHENA_HF_Class50054] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "LVEF<=30")
	(numeric_domain_term Left+Ventricular+Ejection+fraction)
	(operator %3C%3D)
	(value 30.0))

([ATHENA_HF_Class50055] of  Presence_Criterion

	(domain_term Ischemic+Heart+Disease)
	(entry_type Note_Entry)
	(label "presence of ischemic heart disease")
	(presence TRUE))

([ATHENA_HF_Class50057] of  Relative_Time_Interval_Definite

	(how_many "41")
	(label "41days before today")
	(polarity Before)
	(relative_time_point [time%3AINSTANCE_1])
	(time_unit day))

([ATHENA_HF_Class50058] of  Conditional_On_Screen_Message

	(label "Refer cardiology for ICD (non-ischemic cardiomyopathy)")
	(message "Placement of an ICD might be considered in patients without HF who have nonischemic cardiomyopathy and an LVEF less than or equal to 30% who are in NYHA functional class I with chronic optimal medical therapy and have a reasonable expectation of survival with good functional status for more than 1 year.\nIf this is the case refer to cardiology.")
	(message_type Class+II+b)
	(rule_in_condition [ATHENA_HF_Class50059]))

([ATHENA_HF_Class50059] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50054]
		[ATHENA_HF_Class50060])
	(label "non-ischemic cardiomyopathy and LVEF<=30")
	(operator AND))

([ATHENA_HF_Class50060] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class50032])
	(label "non-ischemic cardiomyopathy")
	(operator AND))

([ATHENA_HF_Class50061] of  On_Screen_Message

	(label "nutritional supplements")
	(message "Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.")
	(message_type Class+III))

([ATHENA_HF_Class50062] of  Conditional_On_Screen_Message

	(label "valvular disease")
	(message "Valve replacement or repair should be recommended for patients with hemodynamically significant valvular stenosis or regurgitation and no symptoms of HF in accordance with contemporary guidelines.")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class50063]))

([ATHENA_HF_Class50063] of  Presence_Criterion

	(domain_term Valvular+heart+disease)
	(entry_type Note_Entry)
	(label "presence of valvular disease")
	(presence TRUE))

([ATHENA_HF_Class50065] of  Conditional_On_Screen_Message

	(label "coronary revascularization")
	(message "Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class50055]))

([ATHENA_HF_Class50067] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50036]
		[ATHENA_HF_Class240003])
	(label "Stage C and EF<=40 and ADR ACE")
	(operator AND))

([ATHENA_HF_Class50068] of  Presence_Criterion

	(domain_term Stage+C+Heart+Failure)
	(entry_type Note_Entry)
	(label "Stage C HF")
	(presence TRUE))

([ATHENA_HF_Class50069] of  Drug_Usage

	(Absolute_Contraindications Heart_Failure)
	(Drug_Class_Name cardiotoxic+interventions)
	(label "cardiotoxic drugs"))

([ATHENA_HF_Class50074] of  Consultation_Guideline

	(first_step [ATHENA_HF_Class50075])
	(label "Stage C consultation template")
	(steps
		[ATHENA_HF_Class50075]
		[ATHENA_HF_Class50076]
		[ATHENA_HF_Class50079]
		[ATHENA_HF_Class50084]
		[ATHENA_HF_Class70011]
		[ATHENA_HF_Class70012]
		[ATHENA_HF_Class70008]
		[ATHENA_HF_Class70009]
		[ATHENA_HF_Class70010]
		[ATHENA_HF_Class50002]
		[ATHENA_HF_Class50003]
		[ATHENA_HF_Class60006]
		[ATHENA_HF_Class60007]
		[ATHENA_HF_Class110384]
		[ATHENA_HF_Class110390])
	(transitions
		[ATHENA_HF_Class50077]
		[ATHENA_HF_Class50080]
		[ATHENA_HF_Class60000]
		[ATHENA_HF_Class60001]
		[ATHENA_HF_Class60002]
		[ATHENA_HF_Class60003]
		[ATHENA_HF_Class70004]
		[ATHENA_HF_Class70005]
		[ATHENA_HF_Class70006]
		[ATHENA_HF_Class70007]
		[ATHENA_HF_Class80008]
		[ATHENA_HF_Class110386]
		[ATHENA_HF_Class110387]
		[ATHENA_HF_Class110391]))

([ATHENA_HF_Class50075] of  Consultation_Branch_Step

	(branches
		[ATHENA_HF_Class50076]
		[ATHENA_HF_Class50079]
		[ATHENA_HF_Class70011]
		[ATHENA_HF_Class70012]
		[ATHENA_HF_Class70008]
		[ATHENA_HF_Class70010]
		[ATHENA_HF_Class70009]
		[ATHENA_HF_Class60007]
		[ATHENA_HF_Class60006]
		[ATHENA_HF_Class50003]
		[ATHENA_HF_Class50002]
		[ATHENA_HF_Class110384]
		[ATHENA_HF_Class50084]
		[ATHENA_HF_Class110390])
	(label "Stage C HF")
	(selection_method all_of))

([ATHENA_HF_Class50076] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class50078])
	(label "Fluid management"))

([ATHENA_HF_Class50077] of  Followed_By

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class50076]))

([ATHENA_HF_Class50078] of  On_Screen_Message

	(label "Fluid management")
	(message_type Recommendation))

([ATHENA_HF_Class50079] of  Consultation_Action_Step

	(actions
		[ATHENA_HF_Class50081]
		[ATHENA_HF_Class50082]
		[ATHENA_HF_Class50083])
	(label "Serial assessments"))

([ATHENA_HF_Class50080] of  Followed_By

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class50079]))

([ATHENA_HF_Class50081] of  On_Screen_Message

	(description "Class I")
	(label "Assess activities of daily living")
	(message "Assess ability of patient to perform routine and desired activities of daily living. (Level of Evidence: C)")
	(message_type Recommendation))

([ATHENA_HF_Class50082] of  On_Screen_Message

	(description "Class I")
	(label "Assess volume status")
	(message "Assess volume status and weight. (Level of Evidence: C)")
	(message_type Recommendation))

([ATHENA_HF_Class50083] of  On_Screen_Message

	(description "Class I")
	(label "Assess use cardiotoxic drugs and behaviors")
	(message "Assess current use of alcohol, tobacco, illicit drugs, “alternative therapies,” and chemotherapy drugs, as well as diet and sodium intake. (Level of Evidence: C)")
	(message_type Recommendation))

([ATHENA_HF_Class50084] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class50086])
	(label "Repeat Echocardiogram"))

([ATHENA_HF_Class50086] of  On_Screen_Message

	(description "Class IIa")
	(label "Repeat Echocardiogram")
	(message "Repeat echocardiogram can provide useful information in patients with HF who have had a change in clinical status or who have experienced or recovered from a clinical event or received treatment that might have had a significant effect on cardiac function. (Level of Evidence: C)")
	(message_type Recommendation))

([ATHENA_HF_Class50087] of  Choice_Step

	(branches
		[ATHENA_HF_Class50089]
		[ATHENA_HF_Class50097]
		[ATHENA_HF_Class50009])
	(label " "))

([ATHENA_HF_Class50088] of  Followed_By

	(%3AFROM [ATHENA_HF_Class10004])
	(%3ATO [ATHENA_HF_Class50087]))

([ATHENA_HF_Class50089] of  Action_Choice

	(actions
		[ATHENA_HF_Class50096]
		[ATHENA_HF_Class70139]
		[ATHENA_HF_Class70140]
		[ATHENA_HF_Class70170]
		[ATHENA_HF_Class70173]
		[ATHENA_HF_Class70188]
		[ATHENA_HF_Class70193]
		[ATHENA_HF_Class70197]
		[ATHENA_HF_Class70199]
		[ATHENA_HF_Class100847]
		[ATHENA_HF_Class110823]
		[ATHENA_HF_Class124168]
		[ATHENA_HF_Class110363]
		[ATHENA_HF_Class110366]
		[ATHENA_HF_Class110368]
		[ATHENA_HF_Class100014]
		[ATHENA_HF_Class100015]
		[KB_261747_Class0])
	(label "General Recommendations")
	(strict_rule_in_condition [ATHENA_HF_Class70622]))

([ATHENA_HF_Class50090] of  Followed_By

	(%3AFROM [ATHENA_HF_Class50087])
	(%3ATO [ATHENA_HF_Class50089]))

([ATHENA_HF_Class50091] of  On_Screen_Message

	(label "Fluid management")
	(message "Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)")
	(message_type Class+I))

([ATHENA_HF_Class50092] of  Guideline_Drug

	(dose_strength_unit mg)
	(drug_usage [ATHENA_HF_Class50037])
	(generic_drug sustained+release+metoprolol+succinate)
	(label "Sustained release metoprolol succinate")
	(starting_dose 12.5))

([ATHENA_HF_Class50093] of  Guideline_Drug

	(generic_drug carvedilol)
	(label "Carvedilol")
	(rule_in [ATHENA_HF_Class50011]))

([ATHENA_HF_Class50094] of  Guideline_Drug

	(drug_usage [ATHENA_HF_Class50037])
	(generic_drug bisoprolol)
	(label "Bisoprolol"))

([ATHENA_HF_Class50096] of  On_Screen_Message

	(label "Exercise")
	(message "Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)")
	(message_type Class+I))

([ATHENA_HF_Class50097] of  Action_Choice

	(actions
		[ATHENA_HF_Class50099]
		[ATHENA_HF_Class50108])
	(label "Referrals")
	(strict_rule_in_condition [criterion_INSTANCE_00001]))

([ATHENA_HF_Class50098] of  Followed_By

	(%3AFROM [ATHENA_HF_Class50087])
	(%3ATO [ATHENA_HF_Class50097]))

([ATHENA_HF_Class50099] of  Conditional_On_Screen_Message

	(description "Class I")
	(label "ICD secondary prevention")
	(message "Patient has an indication for an implantable cardioverter-defibrillator, refer to cardiology.\n (Level of Evidence: A)")
	(message_type Recommendation)
	(rule_in_condition [ATHENA_HF_Class50104]))

([ATHENA_HF_Class50100] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50101]
		[ATHENA_HF_Class50102]
		[ATHENA_HF_Class50103])
	(label "ventricularfibrillation, cardiac arrest or hemodynamically destabilizing ventricular tachycardia")
	(operator OR))

([ATHENA_HF_Class50101] of  Presence_Criterion

	(domain_term cardiac+arrest)
	(entry_type Note_Entry)
	(label "presence of cardiac arrest")
	(presence TRUE))

([ATHENA_HF_Class50102] of  Presence_Criterion

	(domain_term ventricular+fibrillation)
	(entry_type Note_Entry)
	(label "presence of ventricular fibrillation")
	(presence TRUE))

([ATHENA_HF_Class50103] of  Presence_Criterion

	(domain_term hemodynamically+destabilizing+ventricular+tachycardia)
	(entry_type Note_Entry)
	(label "presence of hemodynamically destabilizing ventricular tachycardia")
	(presence TRUE))

([ATHENA_HF_Class50104] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50100]
		[ATHENA_HF_Class30004])
	(label "HF and EF<35 and presence of ventricular tachycardia, cardiac arrest or hemodynamically destabilizing ventricular tachycardi")
	(operator AND))

([ATHENA_HF_Class50105] of  Parameterized_Message

	(label "Indication for ICD")
	(message_type Recommendation))

([ATHENA_HF_Class50107] of  Variable
)

([ATHENA_HF_Class50108] of  Referral

	(description "Class I")
	(label "Refer to cardiology - ICD")
	(rule_in_condition [ATHENA_HF_Class50104])
	(who_to cardiologist))

([ATHENA_HF_Class60000] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class70011]))

([ATHENA_HF_Class60001] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class70012]))

([ATHENA_HF_Class60002] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class70008]))

([ATHENA_HF_Class60003] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class70010]))

([ATHENA_HF_Class60004] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class50002]))

([ATHENA_HF_Class60005] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class50003]))

([ATHENA_HF_Class60006] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70028])
	(label "LV function evaluation")
	(rule_in [ATHENA_HF_Class70032]))

([ATHENA_HF_Class60007] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70026])
	(label "Periodic evaluation")
	(rule_in [criterion_INSTANCE_00001])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class60012] of  Presence_Criterion

	(domain_term Angiotensin_II_receptor_blockers)
	(entry_type Adverse_Reaction)
	(label "Presence of adverse reaction to ARB")
	(presence TRUE))

([ATHENA_HF_Class60014] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50036]
		[ATHENA_HF_Class60012]
		[ATHENA_HF_Class60015]
		[ATHENA_HF_Class60016])
	(label "drug intolerance ACE/ARB OR hypotension OR renal insufficienc")
	(operator OR))

([ATHENA_HF_Class60015] of  Presence_Criterion

	(domain_term Renal_Insufficiency)
	(entry_type Note_Entry)
	(label "presence of renal insufficiency ICD9")
	(presence TRUE))

([ATHENA_HF_Class60016] of  Presence_Criterion

	(domain_term hypotension)
	(entry_type Note_Entry)
	(label "presence of hypotension")
	(presence TRUE))

([ATHENA_HF_Class60044] of  Presence_Criterion

	(domain_term Valvular+heart+disease)
	(entry_type Note_Entry)
	(label "Presence of valvular disease")
	(presence TRUE))

([ATHENA_HF_Class60053] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class10007]
		[ATHENA_HF_Class60054]
		[ATHENA_HF_Class60088])
	(label "Criteria for Stage B HF")
	(operator AND))

([ATHENA_HF_Class60054] of  Presence_Criterion

	(domain_term HF+signs+and+symptoms)
	(entry_type Note_Entry)
	(label "Absence of HF signs and symptoms")
	(presence FALSE))

([ATHENA_HF_Class60066] of  Choice_Step

	(branches [ATHENA_HF_Class60069])
	(label " "))

([ATHENA_HF_Class60067] of  Followed_By

	(%3AFROM [ATHENA_HF_Class10005])
	(%3ATO [ATHENA_HF_Class60066]))

([ATHENA_HF_Class60068] of  Choice_Step

	(branches [ATHENA_HF_Class30017])
	(label " "))

([ATHENA_HF_Class60069] of  Action_Choice

	(label "Stage D management action"))

([ATHENA_HF_Class60070] of  Followed_By

	(%3AFROM [ATHENA_HF_Class60068])
	(%3ATO [ATHENA_HF_Class30017]))

([ATHENA_HF_Class60071] of  Followed_By

	(%3AFROM [ATHENA_HF_Class60066])
	(%3ATO [ATHENA_HF_Class60069]))

([ATHENA_HF_Class60072] of  Presence_Criterion

	(domain_term HF+signs+and+symptoms)
	(entry_type Note_Entry)
	(label "Presence of HF signs and symptoms")
	(presence TRUE))

([ATHENA_HF_Class60088] of  Presence_Criterion

	(domain_term Heart_Failure)
	(entry_type Note_Entry)
	(label "Absence of HF")
	(presence FALSE))

([ATHENA_HF_Class70000] of  Drug_Usage

	(Compelling_Indications HF+%28ICD+or+Symptoms%29+and+LVEF%3C%3D40+and+no+MI)
	(Drug_Class_Name Beta_Blocker+Stage+C+Heart+Failure)
	(formulary_preferred_drug_in_class
		[ATHENA_HF_Class50094]
		[ATHENA_HF_Class50092]
		[ATHENA_HF_Class50093])
	(label "Beta blocker Stage C HF no MI"))

([ATHENA_HF_Class70001] of  Drug_Usage

	(Absolute_Contraindications Bronchospastic_Disease)
	(Compelling_Indications MI+no+HF)
	(Drug_Class_Name Beta+blocker+stage+B+post+MI)
	(formulary_preferred_drug_in_class
		[athena_runtime_INSTANCE_00110]
		[ATHENA_HF_Class50093]
		[ATHENA_HF_Class80002]
		[athena_runtime_INSTANCE_00112]
		[ATHENA_HF_Class80004])
	(label "Beta blocker Stage B HF post MI"))

([ATHENA_HF_Class70002] of  Presence_Criterion

	(domain_term Persistent+HF+signs+and+symptoms)
	(entry_type Note_Entry)
	(label "presence of persistent HF signs and symptoms")
	(presence TRUE))

([ATHENA_HF_Class70004] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class70009]))

([ATHENA_HF_Class70005] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class60007]))

([ATHENA_HF_Class70006] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class60006]))

([ATHENA_HF_Class70007] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class50003]))

([ATHENA_HF_Class70008] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70027])
	(label "atherosclerotic vascular disease control")
	(rule_in [ATHENA_HF_Class70033])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class70009] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70023])
	(label "behavior control")
	(rule_in [criterion_INSTANCE_00001])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class70010] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70022])
	(label "Blood sugar control")
	(rule_in [ATHENA_DM_Eye_Instance_40003])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class70011] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70025])
	(label "Thyroid disorder control;")
	(rule_in [ATHENA_HF_Class70034])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class70012] of  Consultation_Action_Step

	(actions [ATHENA_HF_Class70024])
	(label "Ventricular rate/sinus rhythm  control")
	(rule_in [ATHENA_HF_Class70035])
	(rule_out [ATHENA_HF_Class50043]))

([ATHENA_HF_Class70013] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class70009]))

([ATHENA_HF_Class70014] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class60006]))

([ATHENA_HF_Class70015] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class70008]))

([ATHENA_HF_Class70016] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class60007]))

([ATHENA_HF_Class70017] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class70010]))

([ATHENA_HF_Class70018] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class70012]))

([ATHENA_HF_Class70019] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50001])
	(%3ATO [ATHENA_HF_Class70011]))

([ATHENA_HF_Class70020] of  On_Screen_Message

	(label "Hypertension control message")
	(message "In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary\nguidelines. (Level of Evidence: A)")
	(message_type Class+I))

([ATHENA_HF_Class70021] of  On_Screen_Message

	(label "Lipid disorder control message")
	(message "In patients at high risk for developing HF, lipid disorders should\nbe treated in accordance with contemporary guidelines. (Level of\nEvidence: A)")
	(message_type Class+I))

([ATHENA_HF_Class70022] of  On_Screen_Message

	(label "Blood sugar control message")
	(message "For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)")
	(message_type Class+I))

([ATHENA_HF_Class70023] of  On_Screen_Message

	(label "behavior  control message")
	(message "Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of\nEvidence: C)")
	(message_type Class+I))

([ATHENA_HF_Class70024] of  On_Screen_Message

	(label "Ventricular rate/sinus rhythm  control message")
	(message "Ventricular rate should be controlled or sinus rhythm restored in\npatients with supraventricular tachyarrhythmias who are at high\nrisk for developing HF. (Level of Evidence: B)")
	(message_type Class+I))

([ATHENA_HF_Class70025] of  On_Screen_Message

	(label "Thyroid disorder  control message")
	(message "Thyroid disorders should be treated in accordance with contemporary\nguidelines in patients at high risk for developing HF. (Level\nof Evidence: C)")
	(message_type Class+I))

([ATHENA_HF_Class70026] of  On_Screen_Message

	(label "Periodic evaluation message")
	(message "Healthcare providers should perform periodic evaluation for signs\nand symptoms of HF in patients at high risk for developing HF.\n(Level of Evidence: C)")
	(message_type Class+I))

([ATHENA_HF_Class70027] of  On_Screen_Message

	(label "atherosclerotic vascular disease control message")
	(message "In patients at high risk for developing HF who have known\natherosclerotic vascular disease, healthcare providers should\nfollow current guidelines for secondary prevention. (Level of\nEvidence: C)")
	(message_type Class+I))

([ATHENA_HF_Class70028] of  On_Screen_Message

	(label "LV function evaluation message")
	(message "Healthcare providers should perform a noninvasive evaluation of\nLV function (i.e., LVEF) in patients with a strong family history of\ncardiomyopathy or in those receiving cardiotoxic interventions.\n(Level of Evidence: C)")
	(message_type Class+I))

([ATHENA_HF_Class70029] of  N_ary_Criterion

	(criteria [athena_hypertension_INSTANCE_00004])
	(label "BP not under control")
	(operator NOT))

([ATHENA_HF_Class70030] of  N_ary_Criterion

	(label "DM and BP not under control")
	(operator AND))

([ATHENA_HF_Class70031] of  N_ary_Criterion

	(criteria [NCEPATPIII_Instance_40036])
	(label "Lipid not under control")
	(operator NOT))

([ATHENA_HF_Class70032] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class90208]
		[ATHENA_HF_Class90209])
	(label "strong family history of cardiomyopathy or in those receiving cardiotoxic interventions")
	(operator OR))

([ATHENA_HF_Class70033] of  Presence_Criterion

	(domain_term atherosclerotic_vascular_disease)
	(entry_type Note_Entry)
	(label "Presence of atherosclerotic vascular disease")
	(presence TRUE))

([ATHENA_HF_Class70034] of  Presence_Criterion

	(domain_term thyroid+disorders)
	(entry_type Note_Entry)
	(label "Presence of Thyroid Disorder")
	(presence TRUE))

([ATHENA_HF_Class70035] of  Presence_Criterion

	(domain_term supraventricular+tachyarrhythmias)
	(entry_type Note_Entry)
	(label "Presence of supraventricular tachyarrhythmias")
	(presence TRUE))

([ATHENA_HF_Class70036] of  N_ary_Criterion

	(criteria
		[ATHENA_DM_Eye_Instance_40003]
		[ATHENA_HF_Class50031]
		[ATHENA_HF_Class70033])
	(label "DM or HTN or atherosclerotic vascular disease")
	(operator OR))

([ATHENA_HF_Class70037] of  Evaluate_Start_Activity

	(activity_class "Medication")
	(alternatives
		[ATHENA_HF_Class10000]
		[ATHENA_HF_Class30018])
	(label "Evaluate ACE and ARB"))

([ATHENA_HF_Class70039] of  N_ary_Criterion

	(criteria
		[ATHENA_DM_Eye_Instance_40003]
		[ATHENA_HF_Class50031]
		[ATHENA_HF_Class70033])
	(label "High Risk for HF and DM, HTN, or atherosclerotic vascular disease")
	(operator OR))

([ATHENA_HF_Class70041] of  Presence_Criterion

	(domain_term at+risk+for+developing+HF)
	(entry_type Note_Entry)
	(label "hgiht risk for developing HF")
	(presence TRUE))

([ATHENA_HF_Class70043] of  Guideline_View

	(drug_usages
		[ATHENA_HF_Class10000]
		[ATHENA_HF_Class70157]
		[ATHENA_HF_Class30018]
		[ATHENA_HF_Class50037]
		[ATHENA_HF_Class50069]
		[ATHENA_HF_Class50046]
		[ATHENA_HF_Class70183]
		[ATHENA_HF_Class50045]
		[ATHENA_HF_Class80000]
		[ATHENA_HF_Class70001]
		[ATHENA_HF_Class70000]
		[ATHENA_HF_Class90000]
		[ATHENA_HF_Class50045])
	(guideline [ATHENA_HF_Class0])
	(guideline_drugs
		[ATHENA_HF_Class50094]
		[ATHENA_HF_Class10001]
		[ATHENA_HF_Class50093]
		[ATHENA_HF_Class50042]
		[ATHENA_HF_Class50040]
		[ATHENA_HF_Class50092]))

([ATHENA_HF_Class70138] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class60054]
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50036]
		[ATHENA_HF_Class60088]
		[ATHENA_HF_Class10007])
	(label "Stage B and LVEF<=40 and ADR ACE")
	(operator AND))

([ATHENA_HF_Class70139] of  Conditional_On_Screen_Message

	(label "ICD secondary prev rec Stage C")
	(message "An implantable cardioverter-defibrillator is recommended as secondary prevention to prolong survival in patients with current or prior symptoms of HF and reduced LVEF who have a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia. (Level of Evidence: A)")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class50104]))

([ATHENA_HF_Class70140] of  Conditional_On_Screen_Message

	(label "ICD primary prev rec Stage C")
	(message "Implantable cardioverter-defibrillator therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in patients with non-ischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI, a LVEF less than or equal to 35%, and NYHA functional class II or III symptoms while receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A)")
	(message_type Class+I)
	(rule_in_condition [ATHENA_HF_Class70141]))

([ATHENA_HF_Class70141] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class100434])
	(label "LVEF<= 35 and (non isch dilated cardiomyopathy OR MI>40days old")
	(operator AND))

([ATHENA_HF_Class70142] of  Numeric_Term_Criterion

	(entry_type Numeric_Entry)
	(label "LVEF <=35")
	(numeric_domain_term Left+Ventricular+Ejection+fraction)
	(operator %3C%3D)
	(value 35.0))

([ATHENA_HF_Class70143] of  Presence_Criterion

	(domain_term nonischemic+cardiomyopathy)
	(entry_type Note_Entry)
	(label "Presence of non ischemic heart disease")
	(presence TRUE))

([ATHENA_HF_Class70145] of  Presence_Criterion

	(domain_term non-ischemic+dilated+cardiomyopathy)
	(entry_type Note_Entry)
	(label "presence of non-ischemic dilated cardiomyopathy")
	(presence TRUE))

([ATHENA_HF_Class70148] of  Relative_Time_Interval_Definite

	(how_many "40")
	(label ">40 days")
	(polarity Before)
	(relative_time_point [time%3AINSTANCE_1])
	(time_unit day))

([ATHENA_HF_Class70151] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70152]
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class70156]
		[ATHENA_HF_Class70168]
		[ATHENA_HF_Class70169])
	(label "African american and moderate symptoms and using ACE, BB, diureti")
	(operator AND))

([ATHENA_HF_Class70152] of  Presence_Criterion

	(domain_term Black_Non-Hispanic)
	(entry_type Note_Entry)
	(label "African american")
	(presence TRUE))

([ATHENA_HF_Class70153] of  Qualitative_Data

	(label "moderate HF symptoms")
	(sensitive FALSE))

([ATHENA_HF_Class70154] of  Qualitative_Data

	(label "severe HF symptoms")
	(sensitive FALSE))

([ATHENA_HF_Class70155] of  Qualitative_Data

	(sensitive FALSE))

([ATHENA_HF_Class70156] of  Presence_Criterion

	(domain_term Moderate+HF+signs+and+symptoms)
	(entry_type Note_Entry)
	(label "presence of moderate HF symptoms")
	(presence TRUE))

([ATHENA_HF_Class70157] of  Drug_Usage

	(Absolute_Contraindications
		Female+and+most+recent+creatinine++%3E2
		Male+and+most+recent+creatinine%3E2.5
		Acitve+prescription+for+ACE+and+ARB
		Renal_Insufficiency)
	(collateral_actions [ATHENA_HF_Class70166])
	(Compelling_Indications HF+and+LVEF%3C%3D35+%26+HF+%26+moderate%2Fsevere+symptoms+%26+low+creatinine+%26+K%3C5)
	(Drug_Class_Name aldosterone+antagonist)
	(label "Aldosterone antagonist"))

([ATHENA_HF_Class70159] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "Most recent K>=5")
	(numeric_domain_term Potassium)
	(operator %3E%3D)
	(value 5.0))

([ATHENA_HF_Class70161] of  N_ary_Criterion

	(criteria
		[ATHENA_CKD_Instance_70005]
		[ATHENA_HF_Class70162])
	(label "Male and creatinine  >2.5")
	(operator AND))

([ATHENA_HF_Class70162] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "creatinine  >2.5")
	(numeric_domain_term Creatinine)
	(operator %3E)
	(value 2.5))

([ATHENA_HF_Class70164] of  N_ary_Criterion

	(criteria
		[ATHENA_CKD_Instance_40003]
		[ATHENA_HF_Class70165])
	(label "Female and most recent creatinine  >2")
	(operator AND))

([ATHENA_HF_Class70165] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "creatinine >2")
	(numeric_domain_term Creatinine)
	(operator %3E)
	(value 2.0))

([ATHENA_HF_Class70166] of  Collateral_Action

	(actions
		[ATHENA_HF_Class70167]
		[ATHENA_HF_Class110353])
	(label "Add Aldosterone antagonist warning")
	(mood Recommend_Add))

([ATHENA_HF_Class70167] of  On_Screen_Message

	(label "Aldosterone antagonist warning")
	(message "Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.")
	(message_type Recommendation))

([ATHENA_HF_Class70168] of  Presence_Criterion

	(domain_term Beta-Blockers)
	(entry_type Medication)
	(label "presence of beta blocker")
	(presence TRUE))

([ATHENA_HF_Class70169] of  Presence_Criterion

	(domain_term Diuretics)
	(entry_type Medication)
	(label "presence of diuretics")
	(presence TRUE))

([ATHENA_HF_Class70170] of  Conditional_On_Screen_Message

	(label "atrial fibrillation and HF")
	(message "It is reasonable to treat patients with atrial fibrillation and HF with a strategy to maintain sinus rhythm or with a strategy to control ventricular rate alone. (Level of Evidence: A)")
	(message_type Class+II+a)
	(rule_in_condition [ATHENA_HF_Class70171]))

([ATHENA_HF_Class70171] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class30004]
		[ATHENA_HF_Class70172])
	(label "HF and atrial fibrillation")
	(operator AND))

([ATHENA_HF_Class70172] of  Presence_Criterion

	(domain_term Atrial_Fibrillation)
	(entry_type Note_Entry)
	(label "presence of atrial fibrillation")
	(presence TRUE))

([ATHENA_HF_Class70173] of  On_Screen_Message

	(label "Maximal exercise testing")
	(message "Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)")
	(message_type Class+II+a))

([ATHENA_HF_Class70179] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class70180]
		[athena_hypertension_203766])
	(label "Mild-moderate HF symptoms and LVEF<= 40 and ADR ACE")
	(operator AND))

([ATHENA_HF_Class70180] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70156]
		[ATHENA_HF_Class70181])
	(label "Presence of  mild or moderate HF symptoms")
	(operator OR))

([ATHENA_HF_Class70181] of  Presence_Criterion

	(domain_term Mild+HF+signs+and+symptoms)
	(entry_type Note_Entry)
	(label "Presence of  mild HF symptoms")
	(presence TRUE))

([ATHENA_HF_Class70183] of  Drug_Usage

	(collateral_actions [ATHENA_HF_Class110382])
	(Compelling_Indications African+american+and+moderate+symptoms+and+using+ACE%2C+BB%2C+diuretic)
	(Drug_Class_Name Hydralazine_and_nitrates)
	(label "Hydralazine and nitrates")
	(Relative_Indications
		LVEF%3C%3D40+%26+using+ACE+%26+using+BB+%26+HF+symptoms
		LVEF%3C%3D40+and+contraindications+to+ACE%2FARB+%28hypotension%2C+renal+insufficiency+or+drug+intolerance%29))

([ATHENA_HF_Class70185] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50024]
		[ATHENA_HF_Class70168]
		[ATHENA_HF_Class30004]
		[ATHENA_HF_Class70187])
	(label "LVEF<=40 and using ACE and BB and HF and symptomatic")
	(operator AND))

([ATHENA_HF_Class70186] of  Presence_Criterion

	(domain_term Severe+HF+signs+and+symptoms)
	(entry_type Note_Entry)
	(label "Presence of severe HF symptoms")
	(presence TRUE))

([ATHENA_HF_Class70187] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70181]
		[ATHENA_HF_Class70156]
		[ATHENA_HF_Class70186])
	(label "mild or moderate or severe HF symptoms")
	(operator OR))

([ATHENA_HF_Class70188] of  Conditional_On_Screen_Message

	(label "CRT when LVEF<=35% and QRS>=0.12s and atrial fibrillation")
	(message "For patients who have LVEF less than or equal to 35%, a QRS duration of greater than or equal to 0.12 seconds, and atrial fibrillation (AF), CRT with or without an ICD is reasonable for the treatment of NYHA functional class III or ambulatory class IV heart failure symptoms on optimal recommended medical therapy. (Level of Evidence: B)")
	(message_type Class+II+a)
	(rule_in_condition [ATHENA_HF_Class70189]))

([ATHENA_HF_Class70189] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class70172]
		[ATHENA_HF_Class70192]
		[ATHENA_HF_Class170334])
	(label "LVEF<=35% and QRS>=0.12s and atrial fibrillation and  NYHA functional class III or ambulatory class IV symptoms")
	(operator AND))

([ATHENA_HF_Class70192] of  Numeric_Term_Criterion

	(aggregation_operator most_recent)
	(entry_type Numeric_Entry)
	(label "QRS>= 0.12")
	(numeric_domain_term QRS)
	(operator %3E%3D)
	(value 0.12))

([ATHENA_HF_Class70193] of  Conditional_On_Screen_Message

	(label "CRT  frequent dependence ventricular pacing")
	(message "For patients with LVEF of less than or equal to 35% with NYHA functional class III or ambulatory class IV symptoms who are receiving optimal recommended medical therapy and who have frequent dependence on ventricular pacing, CRT is reasonable (2). (Level of Evidence: C)")
	(message_type Class+II+a)
	(rule_in_condition [ATHENA_HF_Class70194]))

([ATHENA_HF_Class70194] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class230011])
	(label "NYHA functional class III or ambulatory class IV symptoms and LVEF<=35%")
	(operator AND))

([ATHENA_HF_Class70195] of  Presence_Criterion

	(domain_term NYHA+functional+class+III+ambulatory+class+IV+symptoms)
	(entry_type Note_Entry)
	(label "Presence of  NYHA functional class III or ambulatory class IV symptoms")
	(presence TRUE))

([ATHENA_HF_Class70197] of  Conditional_On_Screen_Message

	(label "nutritional supplements and stage C")
	(message "Use of NUTRITIONAL SUPPLEMENTS as treatment for HF is NOT INDICATED in patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)")
	(message_type Class+III)
	(rule_in_condition [ATHENA_HF_Class70198]))

([ATHENA_HF_Class70198] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class100853])
	(label "(HF ICD9 or symptoms) and LVEF<=40")
	(operator AND))

([ATHENA_HF_Class70199] of  Conditional_On_Screen_Message

	(label "hormonal therapies and stage C")
	(message "HORMONAL THERAPIES other than to replete deficiencies are NOT RECOMMENDED and may be harmful to patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)")
	(message_type Class+III)
	(rule_in_condition [ATHENA_HF_Class70198]))

([ATHENA_HF_Class70622] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50043]
		[ATHENA_HF_Class70623])
	(label "HF ICD9 code OR( signs and structural abnormality)")
	(operator OR))

([ATHENA_HF_Class70623] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class10007])
	(label "HF signs/symptoms and structural abnormality of heart")
	(operator AND))

([ATHENA_HF_Class70628] of  Presence_Criterion

	(domain_term Low_Ejection_Fraction)
	(entry_type Note_Entry)
	(label "Low Ejection Fraction")
	(presence TRUE))

([ATHENA_HF_Class80000] of  Drug_Usage

	(Compelling_Indications LVEF%3C%3D40+and+no+HF+and+no+MI)
	(Drug_Class_Name Beta+Blocker+Stage+B+no+MI)
	(label "Beta Blocker Stage B HF no MI"))

([ATHENA_HF_Class80002] of  Guideline_Drug

	(generic_drug sustained+release+metoprolol+tartrate)
	(label "metoprolol tartrate"))

([ATHENA_HF_Class80004] of  Guideline_Drug

	(generic_drug timolol)
	(label "timolol"))

([ATHENA_HF_Class80008] of  Consultation_Selection

	(%3AFROM [ATHENA_HF_Class50075])
	(%3ATO [ATHENA_HF_Class50002]))

([ATHENA_HF_Class80352] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class30004])
	(label "HF ICD9 and LVEF<=40")
	(operator AND))

([ATHENA_HF_Class80353] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[athena_hypertension_INSTANCE_00377]
		[ATHENA_HF_Class100851]
		[ATHENA_HF_Class133534])
	(label "HF and LVEF<=40 & moderate/severe symptoms & ((creatinine<=2.5 and male) OR (creatinine<=2 female)) & K<5")
	(operator AND))

([ATHENA_HF_Class80354] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class60072])
	(label "HF symptoms and LVEF<=40")
	(operator AND))

([ATHENA_HF_Class80356] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[athena_hypertension_domain_INSTANCE_00002]
		[ATHENA_HF_Class60054])
	(label "LVEF<=40 and no HF symptoms")
	(operator AND))

([ATHENA_HF_Class90000] of  Drug_Usage

	(collateral_actions [KB_899077_Class8])
	(Compelling_Indications HF+%28ICD+or+Symptoms%29+and+LVEF%3C%3D40+and+MI)
	(Drug_Class_Name carvedilol)
	(formulary_preferred_drug_in_class [ATHENA_HF_Class50093])
	(label "Beta blocker Stage C with MI"))

([ATHENA_HF_Class90002] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class50019]
		[ATHENA_HF_Class50018]
		[ATHENA_HF_Class60088])
	(label "LVEF<=40 and no HF and no MI")
	(operator AND))

([ATHENA_HF_Class90005] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class60088]
		[ATHENA_HF_Class50011])
	(label "MI and no HF")
	(operator AND))

([ATHENA_HF_Class90208] of  Presence_Criterion

	(domain_term family+history+of+cardiomyopathy)
	(entry_type Note_Entry)
	(label "Family history of cardiomopathy")
	(presence TRUE))

([ATHENA_HF_Class90209] of  Presence_Criterion

	(domain_term cardiotoxic+interventions)
	(entry_type Medication)
	(label "Presence of cardiotoxicity drug")
	(presence TRUE))

([ATHENA_HF_Class90384] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class90385])
	(label "Absence of MI within 41 days")
	(operator NOT))

([ATHENA_HF_Class90385] of  Presence_Criterion

	(domain_term Myocardial_Infarction)
	(entry_type Note_Entry)
	(label "Presence of MI within 41 days")
	(period [ATHENA_HF_Class50057])
	(presence TRUE))

([cardiologist] of  Canonical_Terms_Metaclass

	(data_source VISTA_data_element))

([cardiotoxic+antiarrythmic+drugs] of  Medications_Metaclass

	(data_source VISTA_data_element))

([cardiotoxic+CA+channel+blockers] of  Medications_Metaclass

	(data_source VISTA_data_element))

([cifenline] of  Medications_Metaclass

	(data_source VISTA_data_element))

([Class+II+a] of  Canonical_Terms_Metaclass
)

([Class+II+b] of  Canonical_Terms_Metaclass
)

([Class+III] of  Canonical_Terms_Metaclass
)

([CompellingIndAfrican+american+and+moderate+symptoms+and+using+ACE%2C+BB%2C+diuretichydralazine+and+nitrates] of  Drug_Indication_Relation

	(degree compelling)
	(indication African+american+and+moderate+symptoms+and+using+ACE%2C+BB%2C+diuretic))

([CompellingIndHF+symptoms%2FHF+and+LVEF%3C%3D40ACE_Inhibitors] of  Drug_Indication_Relation

	(degree compelling)
	(indication HF+and+LVEF%3C%3D35+%26+HF+%26+moderate%2Fsevere+symptoms+%26+low+creatinine+%26+K%3C5))

([CompellingIndHF+symptoms%2FHF+and+LVEF%3C%3D40aldosterone+antagonist] of  Drug_Indication_Relation

	(degree compelling)
	(indication HF+and+LVEF%3C%3D35+%26+HF+%26+moderate%2Fsevere+symptoms+%26+low+creatinine+%26+K%3C5))

([CompellingIndHF+symptoms%2FHF+and+LVEF%3C%3D40Beta-Blockers] of  Drug_Indication_Relation

	(degree compelling)
	(indication HF+and+LVEF%3C%3D35+%26+HF+%26+moderate%2Fsevere+symptoms+%26+low+creatinine+%26+K%3C5))

([CompellingIndLVEF%3C%3D40+and+no+HF+symptomsACE_Inhibitors] of  Drug_Indication_Relation

	(degree compelling)
	(indication LVEF%3C%3D40+and+no+HF+symptoms))

([CompellingIndLVEF%3C%3D40+and+no+HF+symptomsBeta-Blockers] of  Drug_Indication_Relation

	(degree compelling)
	(indication LVEF%3C%3D40+and+no+HF+symptoms))

([CompellingIndMI+and+LVEF%3C%3D40+and+ADR+ACEAngiotensin_II_receptor_blockers] of  Drug_Indication_Relation

	(degree compelling)
	(indication No+HF%2C+MI%2C++LVEF%3C%3D40+and+ADR+ACE))

([CompellingIndMyocardial_InfarctionACE_Inhibitors] of  Drug_Indication_Relation

	(degree compelling)
	(indication Myocardial_Infarction))

([CompellingIndMyocardial_InfarctionBeta-Blockers] of  Drug_Indication_Relation

	(degree compelling)
	(indication Myocardial_Infarction))

([CompellingIndStage+C+and+LVEF%3C%3D40+and+ADR+ACEAngiotensin_II_receptor_blockers] of  Drug_Indication_Relation

	(degree compelling)
	(indication Stage+C+and+LVEF%3C%3D40+and+ADR+ACE))

([disopyramide] of  Medications_Metaclass

	(data_source VISTA_data_element))

([drug+intolerance+ACE%2FARB+OR+hypotension+OR+renal+insufficiency] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class60014]))

([eGFR%3C30] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class110374]))

([fatigue] of  Canonical_Terms_Metaclass

	(data_source clinical_assessment))

([Female+and+most+recent+creatinine++%3E2] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class70164]))

([Heart+Failure+Stage] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment))

([HF+%26+LVEF%3C%3D35+%26+%28IF+moderate+or+severe+symptoms%29] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class150003]))

([HF+%28ICD+or+Symptoms%29+and+LVEF%3C%3D40+and+MI] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext clinical_assessment)
	(DiagnosticCriteria [ATHENA_HF_Class100004]))

([HF+%28ICD+or+Symptoms%29+and+LVEF%3C%3D40+and+no+MI] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element clinical_assessment VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class100002]))

([HF+%28ICD9+or+symptoms%29+and+LVEF%3C%3D40] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext clinical_assessment)
	(DiagnosticCriteria [ATHENA_HF_Class70198]))

([HF+and+LVEF%3C%3D35+%26+HF+%26+moderate%2Fsevere+symptoms+%26+low+creatinine+%26+K%3C5] of  Diagnostic_Term_Metaclass

	(data_source clinical_assessment VISTA_freetext VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class130007])
	(PrettyName "Heart Failure & LVEF<=35 & moderate/severe symptoms"))

([HF+with+persistent+symptoms+and+LVEF%3C%3D40+and+treated+with+conventional+therapy] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element clinical_assessment VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class100394])
	(PrettyName "HF with persistent symptoms, low EF using ACE inhibitor and beta blocker"))

([HF_and_+LVEF%3C%3D35_and_IF_NYHA_Class_II_or_Class_III_or_Class_IV] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class180002])
	(PrettyName "HF & LVEF<=35 & (IF NYHA Class II or ClassIII or ClassIV symptoms"))

([HF_and_+LVEF%3C%3D35_and_IF_NYHA_Class_III_or__IV_or_II_and_elevated_BNP] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class190011]))

([HF_and_LVEF%3C%3D35_and_NYHA_Class_III_IV_or_Class_II_and_elevated_BNP] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class190013]))

([HF_and_LVEF_le_40_and_NYHA_II_III_IIV_or_DM] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class240009]))

([High+Risk+for+HF+and+DM%2C+HTN%2C+or+atherosclerotic+vascular+disease] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class144252]))

([HTN+and+LVH] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class50030]))

([Hydralazine_and_nitrates] of  Medications_Metaclass

	(data_source VISTA_data_element)
	(PrettyName "hydralazine and nitrates"))

([idecainide] of  Medications_Metaclass

	(data_source VISTA_data_element))

([If_moderate_or_severe_symptoms_are_present] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class60054])
	(PrettyName "IF moderate or severe symptoms are present"))

([If_moderate_symptoms_+are_present] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class60054])
	(PrettyName "If moderate symptoms are present"))

([IF_NHYA_Class_II_symptoms] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class60054])
	(PrettyName "IF NYHA Class II symptoms present"))

([IF_NYHA_Class_II_III_IV_symptoms] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class60054])
	(PrettyName "IF NYHA Class II or Class III or Class IV symptoms"))

([IF_NYHA_class_III_IV_symptoms] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class60054])
	(PrettyName "IF NYHA class II-IV symptoms"))

([IF_NYHA_functional_class_II_o_+III_symptoms] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class60054])
	(PrettyName "NYHA functional class II or III symptoms"))

([IF_NYHA_functional_class_III_or+_mbulatory_class_IV_heart_failure_symptoms] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class60054])
	(PrettyName "IF NYHA functional class III or ambulatory class IV heart failure symptoms"))

([indomethacin] of  Medications_Metaclass

	(data_source VISTA_data_element))

([K%3E5.0] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [library_Class30019])
	(PrettyName "Most recent K>5.0"))

([KB_020015_Class216] of  Qualitative_Constant

	(value "Female"))

([KB_020015_Class219] of  Qualitative_Constant

	(value "Male"))

([KB_020015_Class233] of  %3APAL-CONSTRAINT

	(%3APAL-NAME "There exists a compellingly indicated drug that is not already given or contraindicated or has complications")
	(%3APAL-RANGE "(defrange ?drug_usage :FRAME Drug_Usage)\n(defrange ?current_med :FRAME Medication)\n(defrange ?condition :FRAME Note_Entry)\n(defrange ?med_condition :FRAME Note_Entry)\n(defrange ?indication :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_indication :FRAME Diagnostic_Term_Metaclass)\n(defrange ?contraindication :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_contraindication :FRAME Diagnostic_Term_Metaclass)\n(defrange ?complication :FRAME Medical_Conditions_Metaclass)\n(defrange ?derived_complication :FRAME Diagnostic_Term_Metaclass)\n(defrange ?problem :FRAME Note_Entry)")
	(%3APAL-STATEMENT "(exists ?drug_usage\n        (and  (not (exists ?current_med  \n                           (and (patient_id ?current_med \"1305700708195\")\n                                (is-class (drug_name ?current_med))\n                                (subclass-of  (coerce-to-class (drug_name ?current_med)) (Drug_Class_Name ?drug_usage )))))             \n             (not (= (Drug_Class_Name ?drug_usage)(coerce-to-class Loop_diuretics)))\n             (or (exists ?indication\n                         (and (Compelling_Indications ?drug_usage ?indication)\n                              (exists ?condition \n                                      (and (isa-classname (domain_term ?condition))\n                                           (patient_id ?condition \"1305700708195\")\n                                           (equal-or-subclass-of (coerce-to-class (domain_term ?condition)) ?indication)))))\n                 (exists ?derived_indication \n                         (and (Compelling_Indications ?drug_usage ?derived_indication)\n                              (is-derivable ?derived_indication))))\n             (not (exists ?contraindication \n                          (and (Absolute_Contraindications ?drug_usage ?contraindication)\n                               (exists ?med_condition \n                                       (and (patient_id ?med_condition \"1305700708195\")\n                                            (isa-classname (domain_term ?med_condition))\n                                            (equal-or-subclass-of (coerce-to-class (domain_term ?med_condition)) ?contraindication))))))\n             (not (exists ?derived_contraindication\n                          (and (Absolute_Contraindications ?drug_usage ?derived_contraindication)\n                               (is-derivable ?derived_contraindication))))\n             (not (exists ?complication \n                          (and (Complication_Factor ?drug_usage ?complication)\n                               (exists ?problem \n                                       (and (patient_id ?problem \"1305700708195\")\n                                            (isa-classname (domain_term ?problem))\n                                            (equal-or-subclass-of (coerce-to-class (domain_term ?problem)) ?complication))))))\n             (not (exists ?derived_complication\n                          (and (Complication_Factor ?drug_usage ?derived_complication)\n                               (is-derivable ?derived_complication))))\n        )\n)\n\n"))

([KB_020015_Class81] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_065193_Class110] of  Qualitative_Constant

	(value "Male"))

([KB_065193_Class112] of  Qualitative_Constant

	(value "Female"))

([KB_065193_Class84] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_081292_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_081292_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_081292_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_094729_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_094729_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_094729_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_102662_Class216] of  Qualitative_Constant

	(value "Female"))

([KB_102662_Class219] of  Qualitative_Constant

	(value "Male"))

([KB_102662_Class81] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_109062_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_109062_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_109062_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_127550_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_127550_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_127550_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_165774_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_165774_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_165774_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_175204_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_175204_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_175204_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_178456_Class110] of  Qualitative_Constant

	(value "Male"))

([KB_178456_Class112] of  Qualitative_Constant

	(value "Female"))

([KB_178456_Class209] of  Qualitative_Constant

	(value "Female"))

([KB_178456_Class84] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_219870_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_219870_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_219870_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_261747_Class0] of  Evaluate_Start_Activity

	(alternatives
		[ATHENA_HF_Class70000]
		[ATHENA_HF_Class90000]
		[ATHENA_HF_Class10000]
		[ATHENA_HF_Class70157]
		[ATHENA_HF_Class70183])
	(label "Stage C drug recs"))

([KB_304655_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_304655_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_304655_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_306762_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_306762_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_306762_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_315111_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_315111_Class318] of  Qualitative_Constant

	(value "Male"))

([KB_315111_Class320] of  Qualitative_Constant

	(value "Female"))

([KB_376528_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_376528_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_376528_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_377636_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_377636_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_377636_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_390380_Class81] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_408923_Class217] of  Qualitative_Constant

	(value "Female"))

([KB_408923_Class220] of  Qualitative_Constant

	(value "Male"))

([KB_408923_Class81] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_421688_Class89] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_423334_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_423334_Class318] of  Qualitative_Constant

	(value "Male"))

([KB_423334_Class320] of  Qualitative_Constant

	(value "Female"))

([KB_436714_Class462] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_436714_Class490] of  Qualitative_Constant

	(value "Male"))

([KB_436714_Class492] of  Qualitative_Constant

	(value "Female"))

([KB_436714_Class526] of  Presence_Query
)

([KB_442092_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_442092_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_442092_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_444257_Class110] of  Qualitative_Constant

	(value "Male"))

([KB_444257_Class112] of  Qualitative_Constant

	(value "Female"))

([KB_444257_Class209] of  Qualitative_Constant

	(value "Female"))

([KB_444257_Class84] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_451095_Class125] of  Presence_Query

	(entry_type Medication)
	(mood Authorized)
	(qualitative_domain_term "ACE_Inhibitors"))

([KB_451095_Class81] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_459737_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_459737_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_459737_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_469476_Class216] of  Qualitative_Constant

	(value "Female"))

([KB_469476_Class219] of  Qualitative_Constant

	(value "Male"))

([KB_469476_Class81] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_479685_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_479685_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_479685_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_485757_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_485757_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_485757_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_494836_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_494836_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_494836_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_503818_Class81] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_579166_Class133] of  Qualitative_Constant

	(value "Female"))

([KB_579166_Class135] of  Qualitative_Constant

	(value "Male"))

([KB_579166_Class89] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_618647_Class0] of  Evaluate_Substitution_Activity

	(activity_class "Medication")
	(activity_spec Drug_Usage)
	(activity_spec_key [Drug_Class_Name])
	(activity_to_stop [athena_hypertension_495106])
	(alternatives
		[ATHENA_HF_Class260000]
		[ATHENA_HF_Class240006]
		[ATHENA_HF_Class240002]
		[ATHENA_HF_Class90000]
		[ATHENA_HF_Class110018]
		[ATHENA_HF_Class180005])
	(label "Presence of contraindication, eval substituion Astronaut"))

([KB_618647_Class1] of  Action_Choice

	(actions
		[KB_618647_Class0]
		[ATHENA_HF_Class160000]
		[ATHENA_HF_Class230001]
		[ATHENA_HF_Class230003]
		[ATHENA_HF_Class230005])
	(label "Presence of contraindication, Substitute")
	(strict_rule_in_condition [ATHENA_Lipid_Class160247]))

([KB_618647_Class2] of  Followed_By

	(%3AFROM [ATHENA_HF_Class130002])
	(%3ATO [KB_618647_Class1]))

([KB_632464_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_632464_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_632464_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_637536_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_637536_Class318] of  Qualitative_Constant

	(value "Male"))

([KB_637536_Class320] of  Qualitative_Constant

	(value "Female"))

([KB_645796_Class216] of  Qualitative_Constant

	(value "Female"))

([KB_645796_Class219] of  Qualitative_Constant

	(value "Male"))

([KB_645796_Class81] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_671524_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_671524_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_671524_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_697720_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_697720_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_697720_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_699901_Class214] of  Qualitative_Constant

	(value "Female"))

([KB_699901_Class217] of  Qualitative_Constant

	(value "Male"))

([KB_707214_Class0] of  N_ary_Criterion

	(criteria [ATHENA_HF_Class100013])
	(label "Not Stage D HF (refractory end stage HF)")
	(operator NOT))

([KB_753810_Class213] of  Qualitative_Constant

	(value "Female"))

([KB_753810_Class216] of  Qualitative_Constant

	(value "Male"))

([KB_753810_Class79] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_778916_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_778916_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_778916_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_794216_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_794216_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_794216_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_814969_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_814969_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_814969_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_866213_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_866213_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_866213_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_874985_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_874985_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_874985_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_881797_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_881797_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_881797_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_883703_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_883703_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_883703_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_899077_Class0] of  N_ary_Criterion

	(criteria
		[ATHENA_HF_Class70142]
		[ATHENA_HF_Class220017]
		[ATHENA_HF_Class230009])
	(label "LVEF<=35 & NYHA functional class II or III or ambulatory class IV symptoms & GDMT")
	(operator AND)
	(%3ADOCUMENTATION "Removed criteria for CRT\n& QRS >=0.15 & sinus rhythm & LBBB"))

([KB_899077_Class1] of  Collateral_Action

	(actions
		[ATHENA_HF_Class110380]
		[KB_899077_Class2])
	(label "rec add ACE-I Astronaut")
	(mood Recommend_Add))

([KB_899077_Class2] of  On_Screen_Message

	(label "rec add ACE-I dose based on 2013 ACCF/AHA Guideline")
	(message "Refer to 2013 ACCF/AHA Guideline for specific ACE-I starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.")
	(message_type Recommendation))

([KB_899077_Class3] of  Collateral_Action

	(actions [KB_899077_Class4])
	(label "rec add ARB dose Astronaut")
	(mood Recommend_Add))

([KB_899077_Class4] of  On_Screen_Message

	(label "rec add ARB based on 2013 ACCF/AHA guidelines")
	(message "Refer to 2013 ACCF/AHA Guideline (reproduced below)  for specific ARB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.\ncandesartan starting dose 4-8 mg/once; max dose 32 mg once\nlosartan starting dose 25-50 once; max dose 50-150 mg once\nvalsartan 20-40 mg twice; max dose 160 mg twice")
	(message_type Recommendation))

([KB_899077_Class5] of  On_Screen_Message

	(description "rec add AA based on 2013 ACCF/AHA guidelines")
	(label "rec add AA based on 2013 ACCF/AHA guidelines")
	(message "Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific AA starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.\nspironolactone starting dose 12.5 0 25.0 once; max dose 25 mg once or twice\neplerenone starting dose 25 mg once; max dose 50 mg once")
	(message_type Recommendation))

([KB_899077_Class6] of  On_Screen_Message

	(description "rec add BB based on 2013 ACCF/AHA guidelines")
	(label "rec add BB based on 2013 ACCF/AHA guidelines")
	(message "Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific BB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.\nbisoprolol starting dose 1.25 mg once; max dose 10 mg once\ncarvedilol starting dose 3.125 mg twice; max dose 50 mg twice\ncarvedilol CR starting dose 10 mg once; max dose 80 mg once\nmetoprolol succinate ER starting dose 12.5 - 25 mg once; 200 mg once")
	(message_type Recommendation))

([KB_899077_Class7] of  On_Screen_Message

	(label "rec add hydralazine and nitrates based on 2013 ACCF/AHA guideline")
	(message "Refer to 2013 ACCF/AHA Guideline for specific hydraline and nitrates starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.\nfixed dose combination starting dose 37.5 mg hydralazine + 20 mg isosorbide dintrate/ 3x; max dose 75 mg hydralazine + 40 mg isosorbide dinitrate 3x dialy\nhydralazine and isosorbide dinitrate sstarting dose hydralazine 25-50 mg 3 or 4 x daily and isosorbide dintrate 20 to 30 mg 3 or 4 x dialy; max dose hydralazine 300 mg daily in divided doses and isosorbide dintrate 120 mg daily in divided doses")
	(message_type Recommendation))

([KB_899077_Class8] of  Collateral_Action

	(actions [KB_899077_Class6])
	(label "rec add BB Astronaut")
	(mood Recommend_Add))

([KB_899077_Class9] of  Collateral_Action

	(actions
		[KB_899077_Class7]
		[ATHENA_HF_Class240016])
	(label "rec add hydralazine and nitrates Astronaut II")
	(mood Recommend_Add))

([KB_923519_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_923519_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_923519_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_929760_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_929760_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_929760_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_931688_Class216] of  Qualitative_Constant

	(value "Female"))

([KB_931688_Class219] of  Qualitative_Constant

	(value "Male"))

([KB_931688_Class81] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_950991_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_950991_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_950991_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_952347_Class654] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_952347_Class681] of  Qualitative_Constant

	(value "Male"))

([KB_952347_Class683] of  Qualitative_Constant

	(value "Female"))

([KB_963063_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_963063_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_963063_Class319] of  Qualitative_Constant

	(value "Female"))

([KB_994402_Class1131] of  N_ary_Criterion

	(label "Eligibility criteria")
	(operator AND))

([KB_994402_Class1212] of  Qualitative_Constant

	(value "Female"))

([KB_994402_Class1304] of  Qualitative_Constant

	(value "Male"))

([KB_998060_Class290] of  N_ary_Criterion

	(criteria [KB_707214_Class0])
	(label "Eligibility criteria")
	(operator AND))

([KB_998060_Class317] of  Qualitative_Constant

	(value "Male"))

([KB_998060_Class319] of  Qualitative_Constant

	(value "Female"))

([Low_Ejection_Fraction] of  Diagnostic_Term_Metaclass

	(data_source VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class20004])
	(PrettyName "Low ejection fraction (<40)"))

([LVEF%3C%3D40] of  Diagnostic_Term_Metaclass

	(data_source VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class50019])
	(PrettyName "LV Ejection Fraction <= 40"))

([LVEF%3C%3D40+%26+using+ACE+%26+using+BB+%26+HF+symptoms] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element clinical_assessment VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class102530])
	(PrettyName "HF with low EF and persistent symptoms, using ACE and BB"))

([LVEF%3C%3D40+and+contraindications+to+ACE%2FARB+%28hypotension%2C+renal+insufficiency+or+drug+intolerance%29] of  Diagnostic_Term_Metaclass

	(data_source VISTA_freetext VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class100224])
	(PrettyName "HF with low EF,  intolerance to ACE/ARB"))

([LVEF%3C%3D40+and+intolerant+ACE] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class50039]))

([LVEF%3C%3D40+and+MI+or+ACS+Stage+B] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class270003]))

([LVEF%3C%3D40+and+no+HF+and+no+MI] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class90002])
	(PrettyName "LVEF<=40 and no HF and no MI"))

([LVEF%3C%3D40+and+no+HF+symptoms] of  Diagnostic_Term_Metaclass

	(data_source clinical_assessment VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class80356]))

([LVEF%3C%3D40+and+sinus+rhythm+and+Stage+B+and+absence+HF+symptoms] of  Diagnostic_Term_Metaclass

	(data_source clinical_assessment VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class50048]))

([LVEF%3C%3D40+and+using+ACE+and+BB+and+HF+and+symptomatic] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element clinical_assessment VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class70185]))

([Male+and+most+recent+creatinine%3E2.5] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class70161]))

([MI+no+HF] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class90005])
	(PrettyName "MI no HF"))

([Mild+HF+signs+and+symptoms] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment))

([Mild-moderate+HF+symptoms+and+LVEF%3C%3D+40+and+ACE+intolerant] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext clinical_assessment)
	(DiagnosticCriteria [ATHENA_HF_Class70179]))

([Moderate+HF+signs+and+symptoms] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment))

([moricizine] of  Medications_Metaclass

	(data_source VISTA_data_element))

([No+HF%2C+MI%2C++LVEF%3C%3D40+and+ADR+ACE] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class50035]))

([Non+steroidal+anti+inflammatory+drugs] of  Medications_Metaclass

	(data_source VISTA_data_element))

([non-ischemic+dilated+cardiomyopathy] of  Medical_Conditions_Metaclass

	(data_source VISTA_data_element))

([NYHA_functional_class_IV] of  Medical_Conditions_Metaclass

	(PrettyName "NYHA functional class IV"))

([NYHA_functional_class_IV_ambulatory] of  Medical_Conditions_Metaclass

	(PrettyName "NYHA functional class IV ambulatory"))

([Persistent+HF+signs+and+symptoms] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment))

([Prescription++for+ACE+Inhibitor] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class50024]))

([Presence+of+adverse+reaction+to+ACE] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class50036]))

([Presence+of+adverse+reaction+to+ARB] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element)
	(DiagnosticCriteria [ATHENA_HF_Class60012]))

([prior_cardiovascular_hospitalization] of  Medical_Conditions_Metaclass

	(PrettyName "prior cardiovascular hospitalization"))

([Prior_Myocardial_Infarction] of  Canonical_Terms_Metaclass

	(data_source VISTA_data_element)
	(PrettyName "Prior Myocardial Infarction"))

([procainamide] of  Medications_Metaclass

	(data_source VISTA_data_element))

([quinidine] of  Medications_Metaclass

	(data_source VISTA_data_element))

([RelativeIndHF+symptoms%2FHF+and+LVEF%3C%3D40digoxin] of  Drug_Indication_Relation

	(degree relative)
	(indication HF+and+LVEF%3C%3D35+%26+HF+%26+moderate%2Fsevere+symptoms+%26+low+creatinine+%26+K%3C5))

([RelativeIndHTN+and+LVHACE_Inhibitors] of  Drug_Indication_Relation

	(degree relative)
	(indication HTN+and+LVH))

([RelativeIndHTN+and+LVHAngiotensin_II_receptor_blockers] of  Drug_Indication_Relation

	(degree relative)
	(indication HTN+and+LVH))

([RelativeIndMild-moderate+HF+symptoms+and+LVEF%3C%3D+40Angiotensin_II_receptor_blockers] of  Drug_Indication_Relation

	(degree relative)
	(indication Mild-moderate+HF+symptoms+and+LVEF%3C%3D+40+and+ACE+intolerant))

([RelativeIndStage+B+and+LVEF%3C%3D40+and+ADR+ACEAngiotensin_II_receptor_blockers] of  Drug_Indication_Relation

	(degree relative)
	(indication Stage+B+and+LVEF%3C%3D40+and+ADR+ACE))

([Severe+HF+signs+and+symptoms] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment))

([Severe_LVH] of  Canonical_Terms_Metaclass

	(data_source clinical_assessment)
	(PrettyName "Severe LVH"))

([Stage+A+Heart+Failure] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment VISTA_data_element))

([Stage+B+and+LVEF%3C%3D40+and+ADR+ACE] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class70138]))

([Stage+B+Heart+Failure] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment VISTA_data_element VISTA_freetext))

([Stage+C+and+LVEF%3C%3D40+and+ADR+ACE] of  Diagnostic_Term_Metaclass

	(data_source VISTA_data_element VISTA_freetext)
	(DiagnosticCriteria [ATHENA_HF_Class50067]))

([Stage+C+and+LVEF%3C%3D40+and+symptoms+and+ADR+ACE] of  Diagnostic_Term_Metaclass

	(DiagnosticCriteria [ATHENA_HF_Class240004]))

([Stage+C+Heart+Failure] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment VISTA_data_element))

([Stage+D+Heart+Failure] of  Medical_Conditions_Metaclass

	(data_source clinical_assessment VISTA_data_element))

([Valvular+heart+disease] of  Medical_Conditions_Metaclass

	(data_source VISTA_data_element)
	(PrettyName "Valvular heart disease"))
